<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Carbamazepine for schizophrenia - Leucht, S - 2014 | Cochrane Library</title> <meta content="Carbamazepine for schizophrenia - Leucht, S - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001258.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Carbamazepine for schizophrenia - Leucht, S - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001258.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001258.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Carbamazepine for schizophrenia" name="citation_title"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Stefan.Leucht@lrz.tum.de" name="citation_author_email"/> <meta content="Bartosz Helfer" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Markus Dold" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Werner Kissling" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="John McGrath" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD001258.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001258.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001258.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001258.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antimanic Agents [*therapeutic use]; Antipsychotic Agents [*therapeutic use]; Carbamazepine [*therapeutic use]; Combined Modality Therapy [methods]; Randomized Controlled Trials as Topic; Recurrence; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001258.pub3&amp;doi=10.1002/14651858.CD001258.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001258\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001258\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001258.pub3",title:"Carbamazepine for schizophrenia",firstPublishedDate:"May 2, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001258.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001258.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001258.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001258.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001258.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001258.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001258.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001258.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001258.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001258.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3107 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001258.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0176"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0102"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-sec-0160"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/appendices#CD001258-sec-0188"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/table_n/CD001258StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/table_n/CD001258StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Carbamazepine for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#CD001258-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Stefan Leucht</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#CD001258-cr-0003">Bartosz Helfer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#CD001258-cr-0004">Markus Dold</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#CD001258-cr-0005">Werner Kissling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information#CD001258-cr-0006">John McGrath</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information/en#CD001258-sec-0196">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001258.pub3">https://doi.org/10.1002/14651858.CD001258.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001258-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001258-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001258-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001258-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001258-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001258-abs-0001" lang="en"> <section id="CD001258-sec-0001"> <h3 class="title" id="CD001258-sec-0001">Background</h3> <p>Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug. </p> </section> <section id="CD001258-sec-0002"> <h3 class="title" id="CD001258-sec-0002">Objectives</h3> <p>To examine whether carbamazepine or oxcarbazepine alone is an effective treatment for schizophrenia and schizoaffective psychoses and whether carbamazepine or oxcarbazepine augmentation of neuroleptic medication is an effective treatment for the same illnesses. </p> </section> <section id="CD001258-sec-0003"> <h3 class="title" id="CD001258-sec-0003">Search methods</h3> <p>For the original version we searched The Cochrane Schizophrenia Group's Register of Trials (December 2001), <i>The Cochrane Library</i> (Issue 3, 2001), MEDLINE (1966‐2001), EMBASE (1980‐2001), Biological Abstracts (1980‐2001), PsycLIT (1886‐2001) and PSYNDEX (1974‐2001). For the most recent update we searched the Cochrane Schizophrenia Group's Register of Trials in July 2012. We also inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies and authors for additional data. </p> </section> <section id="CD001258-sec-0004"> <h3 class="title" id="CD001258-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) comparing carbamazepine or compounds of the carbamazepine family with placebo or no intervention, whether as sole treatment or as an adjunct to antipsychotic medication for the treatment of schizophrenia and/or schizoaffective psychoses. </p> </section> <section id="CD001258-sec-0005"> <h3 class="title" id="CD001258-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For homogenous dichotomous data we calculated fixed‐effect, risk ratio (RR), with 95% confidence intervals (CIs) on an intention‐to‐treat basis. For continuous data, we calculated mean differences (MD). We assessed the risk of bias for included studies and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD001258-sec-0006"> <h3 class="title" id="CD001258-sec-0006">Main results</h3> <p>The updated search did not reveal any further studies that met our inclusion criteria. The number of included studies therefore remains at 10 with the number of participants randomised still 283. </p> <p>One study comparing carbamazepine with placebo as the sole treatment for schizophrenia was abandoned early due to high relapse rate with 26 out of 31 participants relapsing by three months. No effect of carbamazepine was evident with no difference in relapse between the two groups (1 RCT n = 31, RR 1.07 CI 0.78 to 1.45). Another study compared carbamazepine with antipsychotics as the sole treatment for schizophrenia. No differences in terms of mental state were found when comparing 50% reduction in Brief Psychiatric Rating Scale (BPRS) scores (1 RCT n = 38, RR 1.23 CI 0.78 to 1.92). A favourable effect for carbamazepine was found when more people who received the antipsychotic (perphenazine) had parkinsonism (1 RCT n = 38, RR 0.03 CI 0.00 to 0.043). Eight studies compared adjunctive carbamazepine versus adjunctive placebo, we were able use GRADE for quality of evidence for these results. Adding carbamazepine to antipsychotic treatment was as acceptable as adding placebo with no difference between the numbers leaving the study early from each group (8 RCTs n = 182, RR 0.47 CI 0.16 to 1.35, <i>very low quality evidence</i> ). Carbamazepine augmentation was superior compared with antipsychotics alone in terms of overall global improvement, but participant numbers were low (2 RCTs n = 38, RR 0.57 CI 0.37 to 0.88). There were no differences for the mental state outcome of 50% reduction in BPRS scores (6 RCTs n = 147, RR 0.86 CI 0.67 to 1.12, <i>low quality evidence</i>). Less people in the carbamazepine augmentation group had movement disorders than those taking haloperidol alone (1 RCT n = 20, RR 0.38 CI 0.14 to 1.02). No data were available for the effects of carbamazepine on subgroups of people with schizophrenia and aggressive behaviour, negative symptoms or EEG abnormalities or with schizoaffective disorder. </p> </section> <section id="CD001258-sec-0007"> <h3 class="title" id="CD001258-sec-0007">Authors' conclusions</h3> <p>Based on currently available randomised trial‐derived evidence, carbamazepine cannot be recommended for routine clinical use for treatment or augmentation of antipsychotic treatment of schizophrenia. At present large, simple well‐designed and reported trials are justified ‐ especially if focusing on people with violent episodes and people with schizoaffective disorders or those with both schizophrenia and EEG abnormalities. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001258-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001258-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001258-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001258-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001258-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001258-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001258-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001258-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001258-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001258-abs-0004" lang="en"> <h3>Carbamazepine for schizophrenia</h3> <p>People with schizophrenia will often hear voices or see things (hallucinations) and have strange beliefs (delusions). They may also experience apathy, tiredness, lack of drive and disorganised thoughts and behaviour. These symptoms make schizophrenia a severe illness that affects many people throughout their life. </p> <p>The main treatment for schizophrenia is antipsychotic medication. However, although this medication is successful in treating the majority of people, 5% to 15% will continue to suffer from debilitating symptoms. For these people, several treatment options are available: changing the dose of medication; switching to another antipsychotic drug; or taking additional drugs that are not antipsychotics. Carbamazepine is a drug first used to treat epilepsy in the 1950s. It is also used as a mood stabiliser when people change between ‘high’ and ‘low’ moods (for example bi‐polar affective disorder). Side effects of carbamazepine include: poor coordination, headaches and drowsiness. </p> <p>This review focuses on the effectiveness of carbamazepine for people with schizophrenia. A search of the Cochrane Schizophrenia Group's trials register was carried out July 2012. Ten studies were found with 283 people. Carbamazepine was compared with no active medication (‘dummy’ or placebo treatment), versus an antipsychotic or when taken in addition to an antipsychotic. However, all of the 10 studies were small and information in them was of a poor standard. There is therefore a lack of evidence whether carbamazepine reduces symptoms and side effects in people with schizophrenia or similar mental health problems. Larger well‐designed trials are necessary to provide stronger evidence before carbamazepine can be recommended as a treatment for people with schizophrenia. </p> <p>This plain language summary has been written by a consumer Ben Gray: Service User and Service User Expert. Rethink Mental Illness. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001258-sec-0176" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001258-sec-0176"></div> <h3 class="title" id="CD001258-sec-0177">Implications for practice</h3> <section id="CD001258-sec-0177"> <section id="CD001258-sec-0178"> <h5 class="title">1. For clinicians</h5> <p>Based on currently available randomised trial‐derived evidence, carbamazepine cannot be recommended for routine clinical use for treatment or augmentation of antipsychotic treatment of schizophrenia. For patients with a past history of response to carbamazepine, a trial of the drug may be warranted. For healthcare professionals currently caring for patients who have been receiving carbamazepine as a putative treatment for schizophrenia, clinicians need to weigh up whether this treatment should be stopped. Carbamazepine is associated with a range of adverse effects. If there is no evidence that the treatment has been effective, then it should be gradually tapered off and then stopped altogether. The dose of concomitant antipsychotics may need to be revised in light of the potential pharmacokinetic interactions between carbamazepine and some antipsychotics as antipsychotic plasma levels may rise upon withdrawal. </p> </section> <section id="CD001258-sec-0179"> <h5 class="title">2. For people with schizophrenia</h5> <p>People with schizophrenia should know of the lack of a strong empirical basis for the use of carbamazepine in their illness. If its recommendation is still perused, the recipient of this treatment should expect clear endpoints and duration of treatment to be agreed upon. </p> </section> <section id="CD001258-sec-0180"> <h5 class="title">3. For managers and policy makers</h5> <p>Although idiosyncratic positive responses are always possible, there are no data to support the use of carbamazepine for those with schizophrenia as a routine measure. </p> </section> </section> <h3 class="title" id="CD001258-sec-0181">Implications for research</h3> <section id="CD001258-sec-0181"> <section id="CD001258-sec-0182"> <h5 class="title">1. General</h5> <p>Any future studies should respect standards of measuring outcomes and of reporting data (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>) in order to enhance the comparability of study results (<a href="./references#CD001258-bbs2-0107" title="BegC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA1996;276:637‐9. ">Begg 1996</a>). The fact that several authors (see <a href="#CD001258-sec-0186">Acknowledgements</a>) shared their data with us very much improved the quality of this review. We would like to encourage similar collaboration in the future. The Cochrane Collaboration supports the <a href="http://www.alltrials.net/" target="_blank">ALLTRIALS</a> initiative. </p> </section> <section id="CD001258-sec-0183"> <h5 class="title">2. Specific</h5> <section id="CD001258-sec-0184"> <h6 class="title">2.1 Reviews or additional comparisons</h6> <p><a href="#CD001258-tbl-0002">Table 1</a>, derived from the excluded studies contains suggestions for further reviews or for further comparisons relevant to this review. Because there are so few compelling data suggesting a real effect of carbamazepine for people with schizophrenia it is difficult to know if some of the additional comparisons are warranted. However, they are added in <a href="#CD001258-tbl-0002">Table 1</a> for the sake of completeness. </p> <div class="table" id="CD001258-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reviews or additional comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Additional comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine (+/‐ antipsychotics) versus lithium (+/‐ antipsychotics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0015" title="BellaireW , DemischK , StollK‐D . Carbamazepine vs. lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses [Carbamazepin vs. Lithium. Einsatz in der Prophylaxe rezidivierender affektiver und schizoaffektiver Psychosen]. Münchner Medizinische Wochenschrift1990;132:82‐6. ">Bellaire 1990</a>, <a href="./references#CD001258-bbs2-0034" title="GreilW , Ludwig‐MayerhoferW , ErazoN , EngelRR . Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. European Archives of Psychiatry and Clinical Neuroscience1997;247(1):42‐50. ">Greil 1997</a>, <a href="./references#CD001258-bbs2-0043" title="KahnEM , SchulzSC , PerelJM , AlexanderJE . Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology1990;10(1):54‐7. ">Kahn 1990</a>, <a href="./references#CD001258-bbs2-0052" title="LenziA , LazzeriniF , GrossiE , MassimettiG , PlacidiGF . Use of carbamazepine in acute psychosis: A controlled study. Journal of International Medical Research1986;14(2):78‐84. ">Lenzi 1986</a>, <a href="./references#CD001258-bbs2-0085" title="PlacidiGF , LenziA , LazzeriniF , CassanoGB . The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double‐blind 3‐year trial in 83 patients. Journal of Clinical Psychiatry1986;47(10):490‐4. PlacidiGF , LenziA , RampelloE , AndreaniMF , CassanoGB , GrossiE . Long term‐double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results. In: EmrichHM , OkumaT editor(s). Anticonvulsants in Affective Disorders. Amsterdam: Elsevier, 1984:188‐97. ">Placidi 1986</a>, <a href="./references#CD001258-bbs2-0090" title="SchulzSC , ConleyRR , KahnEM , et al. Nonresponders to neuroleptics: a distinct subtype. Schizophrenia: scientific progress. New York: Oxford University Press, Date of publication and page numbers not indicated. SchulzSC , KahnEM , BakerRW , et al. Lithium and carbamazepine augmentation in treatment‐refractory schizophrenia. The Neuroleptic‐Nonresponsive Patient: Characterization and Treatment. Washington DC: American Psychiatric Press, 1990:111‐36. ">Schulz 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine plus one antipsychotic versus another antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0078" title="OhlmeierMD , JahnK , Wilhelm‐GosslingC , Godecke‐KochT , HoffmannJ , SeifertJ , et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology2007;55(2):81‐8. [MEDLINE: 17570951] ">Ohlmeier 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine versus valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0069" title="Mosca LD//Licciardo JP//CoppolaJL . A double‐blind carbamazepine‐controlled efficacy and safety study of valproate in impulsivity and violence. 11th Congress of The European College of Neuropsychopharmacology; Oct 31 ‐ Nov 4, Paris, France. 1998. [MEDLINE: CONFERENCE ABSTRACT] ">Mosca 1998</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different formulations of carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0077" title="NijdamJR , DoorschotCH , vanBavelLP , LoonenAJ . A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients. Pharmacopsychiatry1992;25(3):145‐9. [MEDLINE: 92342659] ">Nijdam 1992</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxcarbazepine versus lithium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0019" title="CabreraJ , AlbrechtJ , Muller‐OerlinghausenB . Combined preventive treatment of recurrent manic‐depressive disease with lithium and carbamazepine or oxcarbazepine. Nervenarzt1987;58(4):245‐9. ">Cabrera 1987</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Existing review*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine versus typical antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0023" title="CovellNH , WeissmanEM , EssockSM . Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia Bulletin2004;30(2):229‐40. [MEDLINE: 15279042; EMBASE 2004274059] ">Covell 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>New review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adrenochrome semicarbazone for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0094" title="SugermanAA , HyamsL . Electroencephalographic effects of adrenochrome semicarbazone in schizophrenia: quantitative amplitude analysis. Research Communications in Chemical Pathology and Pharmacology1970;1(1):86‐98. [MEDLINE: 72091267; PMID 4944698] ">Sugerman 1970</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydroxyphenamate for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0063" title="MillerMJ , ShettelR , FiedlerHT . Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines. Psychosomatics1965;6(5):340‐2. [MEDLINE: 66013834; PMID 5319246] ">Miller 1965</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rimcazole for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0017" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27(2):103‐6. [MEDLINE: 92021349; PMID 1681560] ">Borison 1991</a>, <a href="./references#CD001258-bbs2-0070" title="MunetzMR , SchulzSC , BellinM , HartyI . Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Development Research1989;16(1):79‐83. [MEDLINE: 83197879; PMID 6342171] ">Munetz 1989</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tybamate for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0060" title="MeshelE , DenberHC . Double‐blind study of tybamate in psychotic patients. Diseases of the Nervous System1967;28(5):311‐3. [MEDLINE: 67165839; PMID 5338174] ">Meshel 1967</a>, <a href="./references#CD001258-bbs2-0061" title="MeshelE , DenberHC . The use of tybamate in psychotic patients. (A further double blind study). Diseases of the Nervous System1968;29(4):243‐5. [MEDLINE: 68271597; PMID 4870945] ">Meshel 1968</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin B6 for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0064" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 add‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. [MEDLINE: 14518160; EMBASE 2003374828; CN‐00440574.] ">Miodownik 2003</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* <a href="./references#CD001258-bbs2-0121" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174] ">Essali 2009</a> </p> </div> </div> </section> <section id="CD001258-sec-0185"> <h6 class="title">2.2 Trials</h6> <p>There seems to be little need to undertake randomised trials investigating the effects of carbamazepine augmentation for people with uncomplicated schizophrenia. Some special indications might, however, still be of research interest. </p> <p>Despite the reintroduction of clozapine, the only drug proven to have superior efficacy than standard drugs for those with treatment‐resistant illness (<a href="./references#CD001258-bbs2-0121" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174] ">Essali 2009</a>), there is a need for the development of treatment strategies when clozapine does not work. The two randomised trials investigating the effects of carbamazepine augmentation for people with treatment‐resistant schizophrenia (<a href="./references#CD001258-bbs2-0004" title="EstorgesJP , LlorcaPM , LanconC , BougerolT , ScottoJC . Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale1991;17(4):307. LlorcaPM , WolfMA , LanconC , BougerolT . Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale1993;19(5):565‐71. ">Llorca 1993</a>; <a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a>) only randomised a total of 66 patients. Even the combined totals lack the power to identify anything but gross differences between groups. Even small differences in outcome may be of great importance in this subgroup and therefore a large simple trial is justified. Clarification of the role of carbamazepine for the treatment of people with both schizophrenia and EEG abnormalities may be warranted. Carbamazepine is used for those with aggressive or violent episodes and its evaluation within trials in this subgroup of people with schizophrenia would be valuable. Carbamazepine is also used for those with schizoaffective disorders but data from placebo‐controlled trials do not exist. The bipolar type of schizoaffective disorder especially warrants further studies. </p> <p>For a suggested design of study please see <a href="#CD001258-tbl-0003">Table 2</a>. </p> <div class="table" id="CD001258-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: random.<br/> Blinding: blind or independent raters.<br/> Duration: minimum one year follow‐up. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: people with schizophrenia whose illness is resistant to treatment; people with psychoses and EEG abnormalities; people with psychoses and aggressive behaviour; and people with schizoaffective disorders.<br/> Age: Sex: male and female.<br/> N = 750. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine/oxcarbazepine alone: any dose.<br/> 2. Placebo (or no intervention).<br/> 3. Carbamazepine/oxcarbazepine in combination with any antipsychotic treatment: any dose.<br/> 4. Placebo (or no intervention) in combination with any antipsychotic treatment.<br/> 5. Antipsychotics alone: any dose. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving the study early.</p> <p>Service utilisation.</p> <p>Global state ‐ no clinically important change.*</p> <p>Relapse.</p> <p>Mental state ‐ no clinically important change.</p> <p>Behaviour ‐ no clinically important change.</p> <p>Social functioning ‐ no clinically important change.<br/> Adverse effects ‐ clinically important general adverse effects*; sudden and unexpected death. </p> <p>Economic outcomes.</p> <p>Satisfaction with treatment.</p> <p>Quality of life.</p> <p>Pharmacokinetic interactions.<br/> <br/> All outcomes by time ‐ short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Primary outcomes of interest.</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001258-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001258-sec-0022"></div> <div class="table" id="CD001258-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Adjunctive carbamazepine + antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>adjunctive Carbamazepine + antipsychotics compared to placebo/no adjunctive treatment + antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with schizophrenia<br/> <b>Settings:</b> Outpatients/ inpatients<br/> <b>Intervention:</b> Adjunctive Carbamazepine + antipsychotics<br/> <b>Comparison:</b> Placebo/no adjunctive treatment + antipsychotics </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo/no adjunctive treatment + antipsychotics</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Adjunctive Carbamazepine + antipsychotics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> <br/> Leaving the study early due to any reason<br/> Follow‐up: mean 7.7 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> <br/> (17 to 145) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> <br/> (0.16 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No clinically important change in general mental state</b> <br/> Scale used: less than 50% BPRS reduction<br/> Follow‐up: mean 6.1 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b> <br/> (418 to 698) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.67 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average endpoint general mental state score</b> <br/> Scale used: Average BPRS endpoint score. Scale from: 0 to 108.<br/> Follow‐up: mean 5.7 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global mental state in the control groups was<br/> <b>BPRS total score points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global mental state in the intervention groups was<br/> <b>0.3 higher</b> <br/> (12.49 lower to 13.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average endpoint positive symptom score</b> </p> <p>Scale used: Mean PANSS positive subscore at endpoint. Scale from: 7 to 49.<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean positive symptoms in the control groups was<br/> <b>PANSS positive subscore</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean positive symptoms in the intervention groups was<br/> <b>4.22 higher</b> <br/> (0.75 to 7.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average endpoint depressive symptom score</b> <br/> Scale used: Hamilton scale at endpoint. Scale from: 0 to 54.<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression in the control groups was<br/> <b>Hamilton scale at endpoint</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression in the intervention groups was<br/> <b>0.35 lower</b> <br/> (2.2 lower to 1.5 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: reporting bias is especially prevalent in this study pool with high risk being a problem in a majority of reports.<br/> <sup>2</sup> Inconsistency: differences between studies (number of events, effects size sometimes in favour of carbamazepine sometimes in favour of no treatment).<br/> <sup>3</sup> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.<br/> <sup>4</sup> Imprecision: 95% confidence interval includes both benefit and harm. Moreover, the number of events was small.<br/> <sup>5</sup> Inconsistency: high heterogeneity of trial results<br/> <sup>6</sup> Imprecision: very small population size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001258-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001258-sec-0023"></div> <section id="CD001258-sec-0024"> <h3 class="title" id="CD001258-sec-0024">Description of the condition</h3> <p>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population world‐wide with little gender differences. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD001258-bbs2-0110" title="CarpenterWT , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% not working (<a href="./references#CD001258-bbs2-0140" title="MarwahaS , JohnsonS . Schizophrenia and employment ? A review. Social Psychiatry and Psychiatric Epidemiology2004;39:337‐49. ">Marvaha 2004</a>) and up to 10% dying (<a href="./references#CD001258-bbs2-0150" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153‐5. ">Tsuang 1978</a>). </p> </section> <section id="CD001258-sec-0025"> <h3 class="title" id="CD001258-sec-0025">Description of the intervention</h3> <p>Carbamazepine is an anticonvulsant and mood‐stabiliser with a tricyclic structure. It has been employed in treatment of a variety of psychiatric disorders, including schizophrenia, where it has been used as an antipsychotic agent. Its steric structure is similar to that of chlorpromazine or imipramine. Typical adverse effects of carbamazepine include: impaired co‐ordination, headaches and drowsiness (<a href="./references#CD001258-bbs2-0143" title="PateLA . Carbamazepine in treatment of the violent psychotic patients. Jefferson Journal of Psychiatry1986;4(1):28‐36. ">Pate 1986</a>). </p> </section> <section id="CD001258-sec-0026"> <h3 class="title" id="CD001258-sec-0026">How the intervention might work</h3> <p>Carbamazepine (C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O, <a href="#CD001258-fig-0001">Figure 1</a>) is a neutral lipophilic substance that can easily cross cell‐membranes and efficiently get into the nervous system. Carbamazepine mainly influences sodium channels by keeping them inactive as well as by potentiation of gamma‐aminobutyric acid (GABA)‐receptors (<a href="./references#CD001258-bbs2-0123" title="GrangerP , BitonB , FaureC , VigeX , DepoortereH , GrahamD , et al. Modulation of the gamma‐aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology1995;47:1189–96. ">Granger 1995</a>; <a href="./references#CD001258-bbs2-0143" title="PateLA . Carbamazepine in treatment of the violent psychotic patients. Jefferson Journal of Psychiatry1986;4(1):28‐36. ">Pate 1986</a>). </p> <div class="figure" id="CD001258-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Carbamazepine" data-id="CD001258-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Carbamazepine</p> </div> </div> </div> </section> <section id="CD001258-sec-0027"> <h3 class="title" id="CD001258-sec-0027">Why it is important to do this review</h3> <p>Despite the introduction of antipsychotic (neuroleptic) medication in the 1950s, there is still a sizeable minority of people with schizophrenia and related conditions that do not have complete remission of symptoms (<a href="./references#CD001258-bbs2-0145" title="SchoolerNR , KeithSJ . Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin1993;29:431‐46. ">Schooler 1993</a>). Over the last 40 years a variety of adjunctive treatments have been used to treat schizophrenia (<a href="./references#CD001258-bbs2-0112" title="ChristisonGW , KirchDG , WyattRJ . When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin1991;17:217‐45. ">Christison 1991</a>). These are often used in addition to antipsychotics, in order to augment any alleviation of symptoms of schizophrenia, but can be used instead of antipsychotics. Treatments such as lithium (indicated for bipolar affective disorder), carbamazepine (or related compounds such as oxcarbazepine), benzodiazepines, beta‐blockers (<a href="./references#CD001258-bbs2-0111" title="CheineM ,  Ahonen J ,  WahlbeckK . Beta‐blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database of Systematic Reviews2001, Issue Issue 3. [DOI: 10.1002/14651858.CD000234] ">Cheine 2001</a>) and electroconvulsive therapy (<a href="./references#CD001258-bbs2-0148" title="TharyanP , AdamsCE . Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD000076.pub2; CD000076] ">Tharyan 2002</a>) have all been used for people whose psychoses did not respond to traditional therapy. The situation has improved somewhat in recent years with the re‐introduction of clozapine which has proven efficacy for those who have not responded to traditional medications (<a href="./references#CD001258-bbs2-0121" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174] ">Essali 2009</a>). However, many people with psychoses have sub‐optimal responses to treatment, and clinicians are faced with the choice of changing to alternate types of medication, or augmenting existing neuroleptics with other drugs or treatments. </p> <p>Carbamazepine is used for the treatment of epilepsy, but is also used to prevent relapse, as a 'mood stabiliser', in bipolar affective illness in a similar fashion to lithium (<a href="./references#CD001258-bbs2-0113" title="DardennesR , EvenC , BangeF , HeimA . Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorder: a meta‐analysis. British Journal of Psychiatry1995;166:378‐81. ">Dardennes 1995</a>). Oxcarbazepine is a related compound that is said to be an improvement on the older 'parent' drug (<a href="./references#CD001258-bbs2-0149" title="TiihonenJ , VartiainenH , HakolaP . Carbamazepine‐induced changes in plasma levels of neuroleptics. Pharmacopsychiatry1995;28:26‐8. ">Tiihonen 1995</a>). In this review we do not examine the efficacy of carbamazepine for mood disorders and the affective psychoses. However, in two companion reviews the impact of lithium and benzodiazepines as sole or adjunctive treatment for schizophrenia and schizoaffective psychoses is examined (<a href="./references#CD001258-bbs2-0137" title="LeuchtS , KisslingW , McGrathJ . Lithium for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD003834.pub2] ">Leucht 2007a</a>; <a href="./references#CD001258-bbs2-0117" title="DoldM , LiC , TardyM , KhorsandV , GilliesD , LeuchtS . Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD006391.pub2] ">Dold 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001258-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001258-sec-0028"></div> <p>To examine whether carbamazepine or oxcarbazepine alone is an effective treatment for schizophrenia and schizoaffective psychoses and whether carbamazepine or oxcarbazepine augmentation of neuroleptic medication is an effective treatment for the same illnesses. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001258-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001258-sec-0029"></div> <section id="CD001258-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001258-sec-0031"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials. If a trial is described as 'double blind' but implies randomisation, we included such trials in a sensitivity analysis (see <a href="#CD001258-sec-0097">Sensitivity analysis</a>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments within carbamazepine/oxcarbazepine, we only included data if the adjunct treatment was evenly distributed between groups and it was only the carbamazepine/ oxcarbazepine that was randomised. </p> </section> <section id="CD001258-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. </p> <p>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so propose to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD001258-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD001258-sec-0034"> <h5 class="title">1. Experimental interventions</h5> <p>1.1 Carbamazepine/oxcarbazepine alone: any dose.<br/> 1.2 Carbamazepine/oxcarbazepine in combination with any antipsychotic treatment: any dose. </p> </section> <section id="CD001258-sec-0035"> <h5 class="title">2. Control interventions</h5> <p>2.1 Placebo (or no intervention).<br/> 2.2 Placebo (or no intervention) in combination with any antipsychotic treatment.<br/> 2.3. Antipsychotics alone: any dose. </p> </section> </section> <section id="CD001258-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We grouped all outcomes by time ‐ short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks). </p> <section id="CD001258-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>No clinically important response to treatment (at least 50% reduction of overall symptoms or at least much improved) </p> </section> <section id="CD001258-sec-0038"> <h5 class="title">Secondary outcomes</h5> <section id="CD001258-sec-0039"> <h6 class="title">1. Leaving the study early</h6> <p>1.1 For specific reasons<br/> 1.2 Acceptability of treatment (leaving the study early for any reason) </p> </section> <section id="CD001258-sec-0040"> <h6 class="title">2. Service utilisation</h6> <p>2.1 Hospital admission<br/> 2.2 Days in hospital<br/> 2.3 Change in hospital status </p> </section> <section id="CD001258-sec-0041"> <h6 class="title">3. Global state</h6> <p>3.1 Relapse ‐ as defined by each of the studies<br/> 3.2 Time to relapse<br/> 3.3 No change in global state<br/> 3.4 Average endpoint global state score<br/> 3.5 Average change in global state scores </p> </section> <section id="CD001258-sec-0042"> <h6 class="title">4. Mental state</h6> <p>4.1 General mental state</p> <p>4.1.1 No clinically important change in general mental state ‐ as defined by each of the studies<br/> 4.1.2 No change in general mental state<br/> 4.1.3 Average endpoint general mental state score<br/> 4.1.4 Average change in general mental state scores </p> <p>4.2 Specific aspects of mental state</p> <p>4.2.1 No clinically significant response in positive symptoms ‐ as defined by each of the studies<br/> 4.2.2 No change in positive symptoms<br/> 4.2.3 Average endpoint positive symptom score<br/> 4.2.4 Average change in positive symptom scores<br/> 4.2.5 No clinically significant response in negative symptoms ‐ as defined by each of the studies<br/> 4.2.6 No change in negative symptoms<br/> 4.2.7 Average endpoint negative symptom score<br/> 4.2.8 Average change in negative symptom scores<br/> 4.2.9 No clinically significant response in depressive symptoms ‐ as defined by each of the studies<br/> 4.2.10 No change in depressive symptoms<br/> 4.2.11 Average endpoint depressive symptom score<br/> 4.2.12 Average change in depressive symptom scores<br/> 4.2.13 No clinically significant response in manic symptoms ‐ as defined by each of the studies<br/> 4.2.14 No change in manic symptoms<br/> 4.2.15 Average endpoint manic symptom score<br/> 4.2.16 Average change in manic symptom scores </p> </section> <section id="CD001258-sec-0043"> <h6 class="title">5. Behaviour</h6> <p>5.1 General behaviour</p> <p>5.1.1 No clinically important change in general behaviour<br/> 5.1.2 No change in general behaviour<br/> 5.1.3 Average endpoint general behaviour score<br/> 5.1.4 Average change in general behaviour scores<br/> 5.1.5 Compulsory administrations of treatment<br/> 5.1.6 Use of further doses of medication </p> <p>5.2 Specific behaviours</p> <p>5.2.1 Self‐harm, including suicide<br/> 5.2.2 Injury to others<br/> 5.2.3 Aggression<br/> 5.2.3.1 No clinically important change in aggression<br/> 5.2.3.2 No change in aggression<br/> 5.2.3.3 Average endpoint aggression score<br/> 5.2.3.4 Average change in aggression scores<br/> 5.2.4 Self‐care<br/> 5.2.4.1 No clinically important change in self‐care<br/> 5.2.4.2 No change in self‐care<br/> 5.2.4.3 Average endpoint self‐care score<br/> 5.2.4.4 Average change in self‐care scores<br/> 5.2.5 Compliance<br/> 5.2.5.1 No clinically important change in compliance<br/> 5.2.5.2 No change in compliance<br/> 5.2.5.3 Average endpoint compliance score<br/> 5.2.5.4 Average change in compliance scores </p> </section> <section id="CD001258-sec-0044"> <h6 class="title">6. Social functioning</h6> <p>6.1 No clinically important effects for social function<br/> 6.2 No effects for social function<br/> 6.3 Average endpoint social functioning score<br/> 6.4 Average change social functioning scores<br/> 6.5 Employment status during trial (employed / unemployed) </p> </section> <section id="CD001258-sec-0045"> <h6 class="title">7. Adverse effects</h6> <p>7.1 Clinically important general adverse effects<br/> 7.2 Any general adverse effects<br/> 7.3 Average endpoint general adverse effect score<br/> 7.4 Average change in general adverse effect scores<br/> 7.5 Clinically important change in specific adverse effects such as movement disorders<br/> 7.6 Any change in specific adverse effects<br/> 7.7 Average endpoint specific adverse effects<br/> 7.8 Average change in specific adverse effects<br/> 7.9 Use of antiparkinsonian treatment </p> </section> <section id="CD001258-sec-0046"> <h6 class="title">8. Sudden and unexpected death</h6> </section> <section id="CD001258-sec-0047"> <h6 class="title">9. Economic outcomes</h6> <p>9.1 Direct costs<br/> 9.2 Indirect costs </p> </section> <section id="CD001258-sec-0048"> <h6 class="title">10. Satisfaction with treatment</h6> <p>10.1 Recipient of care not satisfied with treatment<br/> 10.2 Recipient of care average satisfaction score<br/> 10.3 Recipient of care average change in satisfaction scores<br/> 10.4 Carer not satisfied with treatment<br/> 10.5 Carer average satisfaction score<br/> 10.6 Carer average change in satisfaction scores </p> </section> <section id="CD001258-sec-0049"> <h6 class="title">11. Quality of life</h6> <p>11.1 No clinically important change in quality of life<br/> 11.2 No change in quality of life<br/> 11.3 Average endpoint quality of life score<br/> 11.4 Average change in quality of life scores<br/> 11.5 No clinically important change in specific aspects of quality of life<br/> 11.6 No change in specific aspects of quality of life<br/> 11.7 Average endpoint specific aspects of quality of life<br/> 11.8 Average change in specific aspects of quality of life </p> </section> <section id="CD001258-sec-0050"> <h6 class="title">12. Pharmacokinetic interactions ‐ change of haloperidol plasma levels.</h6> </section> <section id="CD001258-sec-0051"> <h6 class="title">13. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD001258-bbs2-0147" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used GRADE profiler (<a href="./references#CD001258-bbs2-0122" title="GRADE Working Group. GRADE Profiler. Version 3.2. GRADE Working Group, 2004. ">GRADE Profiler</a>) to import data from RevMan 5 (<a href="./references#CD001258-bbs2-0144" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">Review Manager (RevMan)</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ul id="CD001258-list-0001"> <li> <p>Acceptability of treatment ‐ leaving the studies early for any reason</p> </li> <li> <p>No clinically important response to treatment</p> </li> <li> <p>General mental state</p> </li> <li> <p>Specific mental state: positive symptoms</p> </li> <li> <p>Specific mental state: depression</p> </li> <li> <p>Aggressive behaviour</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD001258-sec-0052"> <h3 class="title">Search methods for identification of studies</h3> <p>Search methods for the 2012 update are below, for previous searches please see <a href="./appendices#CD001258-sec-0189">Appendix 1</a>. </p> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD001258-sec-0053"> <h4 class="title">Electronic searches</h4> <section id="CD001258-sec-0054"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register</h5> <p>The Trials Search Co‐ordinator searched the Cochrane Schizophrenia Group's Trials Register (July 2012) </p> <section id="CD001258-sec-0055"> <h6 class="title">1.1 Intervention search</h6> <p>The 'Intervention' field was searched using the phrase:<br/> (*carbama* or *amizepine* or *carbag* or *carbap* or *carbaz* or *carbymal* or *carpaz* or *cephalon* or *degranol* or *epitol* or *finlepsin* or *fokalepsin* or *hermolepsin* or *neurotol* or *neurotop* or *nordotol* or *sirtal* or *tardotol* or *tegret* or *teril* or *timonil* or *trimonil* or *trialeptal* or *trilpetal*)<br/> <br/> The Cochrane Schizophrenia Group's Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). Incoming trials are assigned to existing or new review titles. </p> </section> </section> </section> <section id="CD001258-sec-0056"> <h4 class="title">Searching other resources</h4> <section id="CD001258-sec-0057"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all identified studies for further relevant studies.</p> </section> <section id="CD001258-sec-0058"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD001258-sec-0059"> <h3 class="title" id="CD001258-sec-0059">Data collection and analysis</h3> <p>Methods used in data collection and analysis for this 2012 update are below, for previous methods please see <a href="./appendices#CD001258-sec-0190">Appendix 2</a> </p> <section id="CD001258-sec-0060"> <h4 class="title">Selection of studies</h4> <p>Review authors SL and MD independently inspected all citations from the searches and identified relevant abstracts. Where disputes arose, the full report was acquired for more detailed scrutiny. If citations met inclusion criteria, we obtained full reports of the papers for more detailed inspection. Again, all reports were independently inspected by SL and MD in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification. </p> </section> <section id="CD001258-sec-0061"> <h4 class="title">Data extraction and management</h4> <section id="CD001258-sec-0062"> <h5 class="title">1. Extraction</h5> <p>Review authors MD and BH extracted data from all included studies. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies contacted for clarification. With remaining problems SL helped clarify issues and these final decisions were documented. If data were presented only in graphs and figures, we extracted whenever possible, but only included the data if two review authors independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. </p> </section> <section id="CD001258-sec-0063"> <h5 class="title">2. Management</h5> <section id="CD001258-sec-0064"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD001258-sec-0065"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD001258-bbs2-0139" title="MarshallM , LockwoodA , BradleyC , AdamsCE , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument has not been written or modified by one of the trial lists for that particular trial. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly. </p> </section> <section id="CD001258-sec-0066"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) (<a href="./references#CD001258-bbs2-0128" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD001258-sec-0067"> <h6 class="title">2.4 Skewed data (endpoint data only)</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all endpoint data before inclusion: a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution), (<a href="./references#CD001258-bbs2-0104" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>); c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD001258-bbs2-0132" title="KaySR , OplerLA , FiszbeinA . Positive and negative syndrome scale (PANSS) manual. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. We presented skewed endpoint data from studies of less than 200 participants in other tables within the data and analyses section rather than enter them into a statistical analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered endpoint data from studies with over 200 participants into syntheses. </p> </section> <section id="CD001258-sec-0068"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD001258-sec-0069"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD001258-bbs2-0142" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:790‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD001258-bbs2-0132" title="KaySR , OplerLA , FiszbeinA . Positive and negative syndrome scale (PANSS) manual. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD001258-bbs2-0134" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005</a>; <a href="./references#CD001258-bbs2-0135" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD001258-sec-0070"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for carbamazepine. </p> </section> </section> </section> <section id="CD001258-sec-0071"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review author BH assessed risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001258-bbs2-0128" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. Review author SL supervised the process. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain further information. </p> <p>The level of risk of bias was noted in both the text of the review (<a href="#CD001258-sec-0121">Risk of bias in included studies</a>), the <a href="./references#CD001258-sec-0201" title="">Characteristics of included studies</a> table and <a href="./full#CD001258-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD001258-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <section id="CD001258-sec-0073"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD001258-bbs2-0109" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD001258-bbs2-0115" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. 2000. ">Deeks 2000</a>). The Number Needed to Treat/Harm (NNT/H) statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD001258-bbs2-0129" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD001258-sec-0074"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We prefer not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD001258-sec-0075"> <h4 class="title">Unit of analysis issues</h4> <section id="CD001258-sec-0076"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD001258-bbs2-0116" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD001258-bbs2-0108" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD001258-bbs2-0124" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>Had we included cluster‐randomised trials and clustering had not been accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, if we include cluster studies, we will seek to contact the first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD001258-bbs2-0124" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). If clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but we will adjust for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD001258-bbs2-0118" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC is not reported, it will be assumed to be 0.1 (<a href="./references#CD001258-bbs2-0151" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. [MEDLINE: 10982317] ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD001258-sec-0077"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD001258-bbs2-0120" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD001258-sec-0078"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. If data were binary, these were simply added and combined within the two‐by‐two table. If data were continuous, we combined data following the formula in section 7.7.3.8  (Combining groups) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD001258-sec-0079"> <h4 class="title">Dealing with missing data</h4> <section id="CD001258-sec-0080"> <h5 class="title">1. Overall loss of credibility</h5> <p>We share the concern that at some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD001258-bbs2-0152" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). However, from which degree of attrition onward this is a problem, is unclear. We therefore did not exclude studies on the basis of degree of attrition, but attrition was taken into account in the 'Risk of bias' assessment. </p> </section> <section id="CD001258-sec-0081"> <h5 class="title">2. Binary</h5> <p>We presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). Those leaving the study early were all assumed not to have changed in the given outcome. This rule is conservative for response, because it assumes that those who left the studies early would not have responded to treatment. It is not conservative concerning side effects, however, it would often have been an overestimation of the frequency of side effects if all participants who discontinued had been assumed to have experienced rare side effects. </p> </section> <section id="CD001258-sec-0082"> <h5 class="title">3. Continuous</h5> <section id="CD001258-sec-0083"> <h6 class="title">3.1 Intention‐to‐treat analysis</h6> <p>We used intention‐to‐treat datasets when possible, but included completer data if only these were available. </p> </section> <section id="CD001258-sec-0084"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either 'P' value or 't' values available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001258-bbs2-0128" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001258-bbs2-0128" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics. Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values from the primary outcome. </p> </section> <section id="CD001258-sec-0085"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD001258-bbs2-0136" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). We reproduced these data, but readers should be aware of the problem. </p> </section> </section> </section> <section id="CD001258-sec-0086"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD001258-sec-0087"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, these were fully discussed. </p> </section> <section id="CD001258-sec-0088"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arise these were fully discussed. </p> </section> <section id="CD001258-sec-0089"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD001258-sec-0090"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD001258-sec-0091"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD001258-bbs2-0127" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of an I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<sup>2</sup>  test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD001258-bbs2-0128" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for the heterogeneity (<a href="#CD001258-sec-0094">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD001258-sec-0092"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD001258-bbs2-0119" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001258-bbs2-0128" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes as there were less than 10 studies in all the analyses, and the numbers of participants were similar. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD001258-sec-0093"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. In this review we therefore primarily chose the fixed‐effect model (following our original method). The reader is, however, able to choose to inspect the data using the random‐effects model, and we applied the random‐effects model in a sensitivity analysis of the primary outcome. </p> </section> <section id="CD001258-sec-0094"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD001258-sec-0095"> <h5 class="title">1. Subgroup analyses</h5> <p>We proposed to undertake this review to provide an overview of the effects of carbamazepine for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. The subgroups we planned to analyse included people with treatment‐resistant schizophrenia, people with EEG abnormalities, residual patients who were suffering predominantly from negative symptoms and people with schizoaffective disorder. </p> </section> <section id="CD001258-sec-0096"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, this was reported. First, we investigated whether data had been entered correctly. Second, if data were correct, we looked at whether methodological reasons of the studies accounted for the heterogeneity. Finally, the graph was visually inspected and outlying studies successively removed to see if heterogeneity was restored. When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these. </p> </section> </section> <section id="CD001258-sec-0097"> <h4 class="title">Sensitivity analysis</h4> <p>We only applied sensitivity analyses to the primary outcome of this review.</p> <section id="CD001258-sec-0098"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcome, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies. </p> </section> <section id="CD001258-sec-0099"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding missing SDs data (see <a href="#CD001258-sec-0079">Dealing with missing data</a>), we compared the findings of the primary outcome when we used our assumption compared with complete data only. </p> </section> <section id="CD001258-sec-0100"> <h5 class="title">3. Imputed values</h5> <p>Had we included any cluster‐randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> <section id="CD001258-sec-0101"> <h5 class="title">4. Fixed and random effects</h5> <p>All data were synthesised using a fixed‐effect model, however, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether the greater weights assigned to larger trials with greater event rates, altered the significance of the results compared to the more evenly distributed weights in the random‐effects model. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001258-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001258-sec-0102"></div> <section id="CD001258-sec-0103"> <h3 class="title">Description of studies</h3> <p>For substantive descriptions of studies please see <a href="./references#CD001258-sec-0201" title="">Characteristics of included studies</a> and <a href="./references#CD001258-sec-0202" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD001258-sec-0104"> <h4 class="title">Results of the search</h4> <p>The original strategy identified hundreds of citations but only 10 studies met our inclusion criteria. In the update searches in 2005, 2007 and 2012 there were 24, 23 and eight new references respectively. We have not had any replies from the authors of studies that were classified as 'awaiting assessment' in previous versions of the review and we did not identify any ongoing studies (see <a href="#CD001258-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD001258-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001258-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001258-sec-0105"> <h4 class="title">Included studies</h4> <p>Ten studies were included in analyses. No new studies were included in this update.</p> <section id="CD001258-sec-0106"> <h5 class="title">1. Design</h5> <p>Four of the included studies had a cross‐over design and six were parallel.</p> </section> <section id="CD001258-sec-0107"> <h5 class="title">2. Length of trials</h5> <p>The longest study lasted for 95 days, the shortest, 18. Three out of 10 studies lasted six weeks, and four studies only five weeks. The mean duration of a study was approximately 41 days. </p> </section> <section id="CD001258-sec-0108"> <h5 class="title">3. Participants</h5> <p>In the 10 included studies a total number of 283 participants were randomised. The two biggest studies involved 41 and 42 participants, the two smallest 18 and 13. On average there were about 28 participants in each study. The number of male and female participant is not indicated in two trials. In the remaining eight studies there is a proportion of about 5:2 of men and woman. Mean age of participants in not indicated in three studies. Based on the available data the mean age is around 26 years. </p> </section> <section id="CD001258-sec-0109"> <h5 class="title">4. Setting</h5> <p>The majority of studies were set in hospitals with only one study involving outpatients.</p> </section> <section id="CD001258-sec-0110"> <h5 class="title">5. Interventions</h5> <p>Two studies used carbamazepine as a sole treatment (one of them with a 800 to 120 mg dose range, the other with the mean dose of 1374 mg per day). The remaining eight studies used carbamazepine as an adjunctive treatment. In this case the doses were usually increasing and were at the level of 600 mg per day. </p> </section> <section id="CD001258-sec-0111"> <h5 class="title">6.Outcomes</h5> <section id="CD001258-sec-0112"> <h6 class="title">6.1 Leaving the study early</h6> <p>The numbers of participants leaving the study early were recorded for the categories any reason, adverse events and lack of efficacy. </p> </section> <section id="CD001258-sec-0113"> <h6 class="title">6.2 Side effects</h6> <p>Side effects were reported in only two studies.</p> </section> <section id="CD001258-sec-0114"> <h6 class="title">6.3 Scales</h6> <p>Details of scales that provided usable data are shown below.</p> <section id="CD001258-sec-0115"> <p><b>6.3.1 Clinical Global Impression (CGI)</b></p> <p>CGI (<a href="./references#CD001258-bbs2-0125" title="GuyW . ECDEU assessment manual for psychopharmacology‐revised. Washington, D.C: DHEW. National Institute of Mental Health1976. ">Guy 1976</a>) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven‐point scoring system is usually used with low scores indicating decreased severity and/or greater recovery </p> </section> <section id="CD001258-sec-0116"> <p><b>6.3.2 Brief Psychiatric Rating Scale (BPRS)</b></p> <p>BPRS (<a href="./references#CD001258-bbs2-0142" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:790‐812. ">Overall 1962</a>) is a brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven‐point scale varying from 'not present' (one) to 'extremely severe' (seven). Scoring ranges from 18 ‐126. </p> </section> <section id="CD001258-sec-0117"> <p><b>6.3.3 Scale for the Assessment of Negative Symptoms (SANS)</b></p> <p>SANS (<a href="./references#CD001258-bbs2-0106" title="AndreasenNC . The scale for assessment of positive symptoms. University of Iowa1984. ">Andreasen 1984</a>) is a six‐point scale that gives a global rating of the following negative symptoms: alogia, affective blunting, avolition‐apathy, anhedonia‐asociality and attention impairment. Higher scores indicate more symptoms. </p> </section> <section id="CD001258-sec-0118"> <p><b>6.3.4 Positive and Negative Syndrome Scale (PANSS)</b></p> <p>PANSS (<a href="./references#CD001258-bbs2-0132" title="KaySR , OplerLA , FiszbeinA . Positive and negative syndrome scale (PANSS) manual. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>) is a schizophrenia scale that has 30 items, each of which can be defined on a seven‐point scoring system varying from one ‐ absent to seven ‐extreme. It can be divided into three sub‐scales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P), and negative symptoms (PANSS‐N). A low score indicates lesser severity </p> <p>6.3.5 Hamilton Depression Rating Scale (HAM‐D)</p> <p>The HAM‐D (<a href="./references#CD001258-bbs2-0126" title="HamiltonM . A rating scale of depression. Journal of Neurology, Neurosurgery and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>) is a scale developed to rate symptoms of depression. The original version contains 17 items rated on a three‐ or five‐point scale. Higher total scores mean more symptoms. </p> </section> </section> <section id="CD001258-sec-0119"> <h6 class="title">6.4 Missing outcomes</h6> <p>There were no data on aggression, service use such as 'duration of hospital stay', satisfaction with treatment or costs. </p> </section> </section> </section> <section id="CD001258-sec-0120"> <h4 class="title">Excluded studies</h4> <p>In the 2012 update an additional two studies met some of the inclusion criteria closely enough to be listed as 'excluded studies' (<a href="./references#CD001258-bbs2-0078" title="OhlmeierMD , JahnK , Wilhelm‐GosslingC , Godecke‐KochT , HoffmannJ , SeifertJ , et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology2007;55(2):81‐8. [MEDLINE: 17570951] ">Ohlmeier 2007</a>; <a href="./references#CD001258-bbs2-0038" title="IvkoviM , DamjanoviA , MarinkoviD , PaunoviRV . Carbamazepine for acute psychosis with EEG abnormalities. Military‐Medical and Pharmaceutical Review2004;61(4):399‐403. ">Ivkovi 2004</a>). Thus, the category 'excluded studies' currently lists 91 trials. Sixty‐four trials were not randomised or the randomisation was undertaken inappropriately. Three studies were excluded due to participants not meeting the inclusion criteria, 19 studies due to type of intervention (typically there was no placebo group) and five because no usable outcomes were presented. </p> </section> </section> <section id="CD001258-sec-0121"> <h3 class="title">Risk of bias in included studies</h3> <p>For graphical representations of our judgements of risk of bias please refer to <a href="#CD001258-fig-0003">Figure 3</a> and <a href="#CD001258-fig-0004">Figure 4</a>. Full details of judgements can be seen in the 'Risk of bias' tables. </p> <div class="figure" id="CD001258-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001258-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001258-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001258-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001258-sec-0122"> <h4 class="title">Allocation</h4> <p>Four out of 10 of all the included studies were judged as having a low risk of potential selection bias because a specific method of generating a random sequence was provided (<a href="./references#CD001258-bbs2-0004" title="EstorgesJP , LlorcaPM , LanconC , BougerolT , ScottoJC . Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale1991;17(4):307. LlorcaPM , WolfMA , LanconC , BougerolT . Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale1993;19(5):565‐71. ">Llorca 1993</a>; <a href="./references#CD001258-bbs2-0005" title="MairM , TschapellerI , SchubertH . Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie. In: SchonbeckG , PlatzT editor(s). Schizophrenie erkennen, verstehen, behandeln.Beiträge aus Theorie und Praxis. Wien: Springer Verlag, 1990:77‐92. ">Mair 1990</a>; <a href="./references#CD001258-bbs2-0006" title="Martin‐MunozJC , Morinigo‐DominguezAV , Mateo‐MartinI , GuajardoFI . Carbamazepine: An effective adjunct treatment for schizophrenia [La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines1992;20(1):11‐6. Martin‐MunozJC , Morinigo‐DominguezAV , Mateo‐MartinI , IbarraIG . Carbamazepine: An efficacious adjuvant treatment in schizophrenia [La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines1989;17(4):245‐50. ">Martin‐Munoz 1989</a>; <a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a>). These studies typically used a random number list or a coin toss method. The remaining six studies state simply that the order was randomised without giving any further details about the procedure. All these studies are rated as having an unclear risk of selection bias. No studies were rated as possessing a high risk of selection bias. </p> <p>Only two studies report on allocation concealment (<a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a>; <a href="./references#CD001258-bbs2-0007" title="NachshoniT , LevinY , LevyA , KritzA . A double‐blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry1994;35(1):22‐6. ">Nachshoni 1994</a>). In one of them sealed envelopes were used, in the other only a control psychiatrist had access to the identity of the interventions. The rest of the studies do not provide any informations that could be used to assess allocation concealment, thus they are rated as unclear in this respect. </p> <p>As poor reporting of randomisation has consistently been associated with an overestimate of effect (<a href="./references#CD001258-bbs2-0146" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a>) all the trials rated as “unclear” could have a 30% to 40% overestimate of effect (<a href="./references#CD001258-bbs2-0141" title="MoherD , SchulzKF , AltmanD , CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;258:1987‐91. ">Moher 2001</a>; <a href="./references#CD001258-bbs2-0146" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a>). </p> </section> <section id="CD001258-sec-0123"> <h4 class="title">Blinding</h4> <p>Objective and subjective outcomes were rated separately, because we consider blinding to be less important for objective as it is for subjective outcomes. Performance and detection bias was also rated separately resulting in four independent assessments of blinding. </p> <section id="CD001258-sec-0124"> <h5 class="title">1. Objective</h5> <p>For both performance and detection bias, the vast majority of studies were rated as having a low risk of bias (nine out of 10 studies), because a double‐blind procedure was employed. In only one study such an information was missing, thus is was rated as unclear (<a href="./references#CD001258-bbs2-0010" title="SvestkaJ , CeskovaE , RysanekR , NahunekK . Controlled cross‐over comparison of carbamazepine with perphenazine in schizophrenic psychoses. Activitas Nervosa Superior1989;31(4):276‐7. ">Svestka 1989</a>). </p> </section> <section id="CD001258-sec-0125"> <h5 class="title">2. Subjective</h5> <p>As for subjective outcomes, in terms of blinding of participants and personnel, only two studies provided enough information to be rated as having a low risk of bias (<a href="./references#CD001258-bbs2-0004" title="EstorgesJP , LlorcaPM , LanconC , BougerolT , ScottoJC . Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale1991;17(4):307. LlorcaPM , WolfMA , LanconC , BougerolT . Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale1993;19(5):565‐71. ">Llorca 1993</a>; <a href="./references#CD001258-bbs2-0007" title="NachshoniT , LevinY , LevyA , KritzA . A double‐blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry1994;35(1):22‐6. ">Nachshoni 1994</a>). In both cases rhe use of identical capsules for drug and placebo was reported. The remaining eight studies did not provide any further details, hence they were rated as 'unclear'. The raters were described as blind only in three out of 10 studies (<a href="./references#CD001258-bbs2-0001" title="CarpenterWT , KurzR , KirkpatrickB , HanlonTE . Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry1991;48(1):69‐72. ">Carpenter 1991</a>; <a href="./references#CD001258-bbs2-0004" title="EstorgesJP , LlorcaPM , LanconC , BougerolT , ScottoJC . Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale1991;17(4):307. LlorcaPM , WolfMA , LanconC , BougerolT . Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale1993;19(5):565‐71. ">Llorca 1993</a>; <a href="./references#CD001258-bbs2-0007" title="NachshoniT , LevinY , LevyA , KritzA . A double‐blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry1994;35(1):22‐6. ">Nachshoni 1994</a>. </p> </section> </section> <section id="CD001258-sec-0126"> <h4 class="title">Incomplete outcome data</h4> <p>Eight out of 10 studies were assessed as having a low risk of attrition bias, meaning that the problem of incomplete outcome data was addressed in an appropriate way (the number of dropouts was not very high and was evenly distributed between groups). Only two studies were judged as unclear (<a href="./references#CD001258-bbs2-0005" title="MairM , TschapellerI , SchubertH . Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie. In: SchonbeckG , PlatzT editor(s). Schizophrenie erkennen, verstehen, behandeln.Beiträge aus Theorie und Praxis. Wien: Springer Verlag, 1990:77‐92. ">Mair 1990</a>; <a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a>). One of them did not report on dropouts at all (<a href="./references#CD001258-bbs2-0005" title="MairM , TschapellerI , SchubertH . Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie. In: SchonbeckG , PlatzT editor(s). Schizophrenie erkennen, verstehen, behandeln.Beiträge aus Theorie und Praxis. Wien: Springer Verlag, 1990:77‐92. ">Mair 1990</a>). The other one had an uneven distribution of early discontinuations between groups (<a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a>). </p> </section> <section id="CD001258-sec-0127"> <h4 class="title">Selective reporting</h4> <p>The majority of studies (six out of 10) were judged as having a high risk of reporting bias due to lack of informations about some predefined outcomes. A very typical problem comprised not reporting about standard deviations. Out of the remaining four studies, one was rated as unclear due to the fact that only an abstract with a limited number of information was available (<a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a>). The other three did not selectively report on any outcomes and thus were judged as having a low risk of bias in that respect (<a href="./references#CD001258-bbs2-0001" title="CarpenterWT , KurzR , KirkpatrickB , HanlonTE . Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry1991;48(1):69‐72. ">Carpenter 1991</a>; <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a>; <a href="./references#CD001258-bbs2-0007" title="NachshoniT , LevinY , LevyA , KritzA . A double‐blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry1994;35(1):22‐6. ">Nachshoni 1994</a>). </p> </section> <section id="CD001258-sec-0128"> <h4 class="title">Other potential sources of bias</h4> <p>Nine out of 10 studies were rated as free of other potential sources of bias. Only one study was rated as unclear in this respect, because the dosages of rescue and additional medications differed between groups (no further details were provided) (<a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a>). </p> </section> </section> <section id="CD001258-sec-0129"> <h3 class="title" id="CD001258-sec-0129">Effects of interventions</h3> <p>See: <a href="./full#CD001258-tbl-0001"><b>Summary of findings for the main comparison</b> Adjunctive carbamazepine + antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</a> </p> <p>We used risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout. </p> <section id="CD001258-sec-0130"> <h4 class="title">1. Comparison 1: Carbamazepine as sole treatment versus placebo as sole treatment</h4> <p>Only <a href="./references#CD001258-bbs2-0001" title="CarpenterWT , KurzR , KirkpatrickB , HanlonTE . Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry1991;48(1):69‐72. ">Carpenter 1991</a> compared carbamazepine as a sole agent with placebo in maintenance treatment. </p> <section id="CD001258-sec-0131"> <h5 class="title">1.1 Leaving the study early</h5> <p>One person receiving carbamazepine left early due to a rash and another due to leucopenia. Two people also left early from the placebo group, due to a conduction defect on the ECG and headache, respectively. No difference between groups was found (1 RCT n = 31, RR 1.07 CI 0.17 to 6.64). </p> </section> <section id="CD001258-sec-0132"> <h5 class="title">1.2 Global state ‐ relapse</h5> <p>Data from the first 27 people included into this study showed that carbamazepine was no more effective than placebo in preventing relapse(1 RCT n = 31, RR 1.07 CI 0.78 to 1.45). As the majority of those in both groups (26 out of 31) did relapse, the study was stopped by three months. </p> </section> <section id="CD001258-sec-0133"> <h5 class="title">1.3 Mental state</h5> <p>There was no significant difference in terms of mental state as measured by the number of patients with less than 20% BPRS reduction (1 RCT n = 31, RR 0.99 CI 0.75 to 1.30) or the mean BPRS at endpoint between both groups (1 RCT n = 27, MD ‐0.07 CI ‐0.46 to 0.32). </p> </section> <section id="CD001258-sec-0134"> <h5 class="title">1.4 Adverse effects</h5> <p><a href="./references#CD001258-bbs2-0001" title="CarpenterWT , KurzR , KirkpatrickB , HanlonTE . Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry1991;48(1):69‐72. ">Carpenter 1991</a> reported transient sedation and nausea in the carbamazepine group, although no figures were presented. Three people treated with carbamazepine developed a rash, this difference was not statistically significant (1 RCT n = 31, RR 7.44 CI 0.42 to 132.95), and one person developed leucopenia, again differences between treatment groups were not significant (1 RCT n = 31, RR 3.19 CI 0.14 to 72.69). </p> </section> </section> <section id="CD001258-sec-0135"> <h4 class="title">2. Comparison 2: Carbamazepine as sole treatment versus antipsychotics as sole treatment</h4> <p>Again, only one trial was found that compared carbamazepine with perphenazine in acutely ill patients with schizophrenia and schizoaffective disorder (<a href="./references#CD001258-bbs2-0010" title="SvestkaJ , CeskovaE , RysanekR , NahunekK . Controlled cross‐over comparison of carbamazepine with perphenazine in schizophrenic psychoses. Activitas Nervosa Superior1989;31(4):276‐7. ">Svestka 1989</a>). </p> <section id="CD001258-sec-0136"> <h5 class="title">2.1 Leaving the study early</h5> <p>Two patients on carbamazepine versus none on perphenazine left the study before its end, this difference is not statistically significant (1 RCT n = 38, RR 4.52 CI 0.23 to 88.38). </p> </section> <section id="CD001258-sec-0137"> <h5 class="title">2.2 Mental state</h5> <p>We found no significant differences in terms of mental state. A similar number of people treated with carbamazepine and perphenazine reached less than 20% (1 RCT n = 38, RR 1.29 CI 0.62 to 2.66), 35% (1 RCT n = 38, RR 1.67 CI 0.86 to 3.24) or 50% (1 RCT n = 38, RR 1.23 CI 0.78 to 1.92) BPRS reduction. Again, no significant difference in terms of mean BPRS at endpoint was found (1 RCT n = 38, MD 2.30 CI ‐3.84 to 8.44). However, when those with schizoaffective disorder were excluded, a statistically significant inferiority of carbamazepine in terms of 20% BPRS reduction (1 RCT n = 28, RR 3.09 CI 1.22 to 7.84) and 35% BPRS reduction (1 RCT n = 28, RR 2.32 CI 1.15 to 4.67) was found. This effect was not as evident for 50% BPRS reduction scores and the difference between groups just failed to reach significance (1 RCT n = 28, RR 1.40 CI 0.94 to 2.09). Since only 10 participants had schizoaffective disorder, an analysis of this subgroup was not thought to be meaningful. </p> </section> <section id="CD001258-sec-0138"> <h5 class="title">2.3 Adverse effects</h5> <section id="CD001258-sec-0139"> <h6 class="title">2.3.1 Movement disorders</h6> <p>Significantly more participants who received perphenazine needed antiparkinson medication (1 RCT n = 38, RR 0.23 CI 0.09 to 0.55, NNH 1 CI 1 to 2) or had parkinsonism (1 RCT n = 38, RR 0.03 CI 0.00 to 0.43, NNH 1 CI 0.9 to 1.4). No significant difference in terms of the number of participants with akathisia (1 RCT,n = 38, RR 0.13 CI 0.01 to 2.34) or tremor (1 RCT n = 38, RR 0.30 CI 0.01 to 6.97) was found. </p> </section> <section id="CD001258-sec-0140"> <h6 class="title">2.3.2 Other adverse effects</h6> <p>The following other adverse effects were reported: collapse, dizziness, blurred vision, dryness of mouth, fatigue, nausea, constipation, salivation, tachycardia. Studies found no significant differences between groups. </p> </section> </section> </section> <section id="CD001258-sec-0141"> <h4 class="title">3. Comparison 3: Adjunctive carbamazepine + antipsychotics versus placebo/no adjunctive treatment + antipsychotics </h4> <p>Eight studies compared adding carbamazepine to antipsychotic treatment with adding a placebo to just antipsychotic treatment alone. </p> <section id="CD001258-sec-0142"> <h5 class="title">3.1 Leaving the study early</h5> <p>Eight studies were able to contribute to the outcome of 'number leaving the study early', although four of these studies had no one leave early in either group. No difference was found (8 RCTs n = 182, RR 0.47 CI 0.16 to 1.35) between those allocated to the augmentation group and those taking placebo adjunctive therapy. </p> </section> <section id="CD001258-sec-0143"> <h5 class="title">3.2 Global state</h5> <p>Only <a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a> and <a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a> provided data on the outcome 'no general improvement'. Carbamazepine augmentation of neuroleptics was superior compared to various antipsychotics alone, but the number of patients included was very low (2 RCTs n = 38, RR 0.57 CI 0.37 to 0.88). </p> </section> <section id="CD001258-sec-0144"> <h5 class="title">3.3 Mental state</h5> <section id="CD001258-sec-0145"> <h6 class="title">3.3.1 General</h6> <p>The individual patient data from six studies could be used for the analysis of various degrees of BPRS reduction. No significant differences in terms of number of participants with less than 20% (6 RCTs n = 147, RR 0.69 CI 0.44 to 1.07), 35% (6 RCTs n = 147, RR 0.78 CI 0.57 to 1.05) or 50% BPRS reduction (6 RCTs n = 147, RR 0.86 CI 0.67 to 1.12) were found. The results at the 50% BPRS reduction level were significantly heterogeneous because two studies (<a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a>; <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a>) showed contrary results. No obvious reasons for this heterogeneity could be derived from the publications. This was a general problem of these two studies in a number of efficacy outcomes. Removing both studies did not change statistical significance, therefore we decided to leave them in. Similar equivocal results were found when the mean BPRS (3 RCTs n = 79, MD ‐3.21 CI ‐7.82 to 1.40) was analysed. The results based on the IMPS at endpoint showed a significant superiority of the control group (2 RCTs n = 50, MD 4.61 CI 1.30 to 7.91). However, the results of the two studies were highly heterogeneous and when a random‐effects model instead of the fixed‐effect model was used, there was no significant difference (2 RCTs n = 50, MD 5.2 CI ‐11.1 to 21.4). </p> </section> <section id="CD001258-sec-0146"> <h6 class="title">3.3.2 Specific ‐ positive symptoms, negative symptoms and depression</h6> <p>Only very few data for specific symptoms of schizophrenia could be extracted. In the <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a> study, the participants in the carbamazepine group had, on average, more positive symptoms at endpoint than those in the control group (1 RCT n = 18, MD 4.22 CI 0.75 to 7.69). The <a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a> study showed oppositional results, but the data could only be presented in the 'other data' table because they were skewed (<a href="./references#CD001258-fig-0023" title="">Analysis 3.8</a>). No significant superiority of carbamazepine augmentation in terms of negative symptoms (2 RCTs n = 53, MD ‐2.75 CI ‐6.71 to 1.22) or depression (1 RCT n = 26, MD ‐0.35 CI ‐2.20 to 1.50) could be found. </p> </section> </section> <section id="CD001258-sec-0147"> <h5 class="title">3.4 Behaviour</h5> <p>Two studies presented data on the average dose of additional medication needed for the treatment of agitated behaviour. In <a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a> people receiving carbamazepine augmentation needed less additional medication, whereas in <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a> they needed more additional medication than in the control group. Data were skewed and could therefore only be presented in the other data table (<a href="./references#CD001258-fig-0026" title="">Analysis 3.11</a>). </p> </section> <section id="CD001258-sec-0148"> <h5 class="title">3.5 Adverse effects</h5> <p>Side effects were not well reported in the studies.</p> <section id="CD001258-sec-0149"> <h6 class="title">3.5.1 Movement disorders</h6> <p>The effect of adjunctive carbamazepine on movement disorders is not clear. One small study (<a href="./references#CD001258-bbs2-0006" title="Martin‐MunozJC , Morinigo‐DominguezAV , Mateo‐MartinI , GuajardoFI . Carbamazepine: An effective adjunct treatment for schizophrenia [La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines1992;20(1):11‐6. Martin‐MunozJC , Morinigo‐DominguezAV , Mateo‐MartinI , IbarraIG . Carbamazepine: An efficacious adjuvant treatment in schizophrenia [La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines1989;17(4):245‐50. ">Martin‐Munoz 1989</a>) reported on the binary outcome of 'movement disorder present'. Less people in the carbamazepine augmentation group had movement disorders than those taking haloperidol alone but the result just failed to reach significance (1 RCT n = 20, RR 0.38 CI 0.14 to 1.02). Skewed data from the Simpson‐Angus Scale were equivocal from three studies (<a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a>; <a href="./references#CD001258-bbs2-0007" title="NachshoniT , LevinY , LevyA , KritzA . A double‐blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry1994;35(1):22‐6. ">Nachshoni 1994</a>; <a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a>). </p> <p>Three studies (<a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a>; <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a>; <a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a>) presented data on the mean dose of antiparkinson medication used. These data are presented in the 'other data' tables, because they are skewed (<a href="./references#CD001258-fig-0028" title="">Analysis 3.13</a>). No consistent trend can be derived from these data. </p> </section> <section id="CD001258-sec-0150"> <h6 class="title">3.5.2 Other side effects</h6> <p>Two studies used scales to assess side effects (<a href="./references#CD001258-bbs2-0005" title="MairM , TschapellerI , SchubertH . Kombinationstherapie mit Neuroleptika und Carbamazepin. Eine kontrollierte Studie. In: SchonbeckG , PlatzT editor(s). Schizophrenie erkennen, verstehen, behandeln.Beiträge aus Theorie und Praxis. Wien: Springer Verlag, 1990:77‐92. ">Mair 1990</a>; <a href="./references#CD001258-bbs2-0006" title="Martin‐MunozJC , Morinigo‐DominguezAV , Mateo‐MartinI , GuajardoFI . Carbamazepine: An effective adjunct treatment for schizophrenia [La carbamacepina: un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines1992;20(1):11‐6. Martin‐MunozJC , Morinigo‐DominguezAV , Mateo‐MartinI , IbarraIG . Carbamazepine: An efficacious adjuvant treatment in schizophrenia [La carbamacepina: Un tratamiento adjunto eficaz en las esquizofrenias]. Actas Luso Espanolas de Neurologia, Psiquiatria y Ciencias Afines1989;17(4):245‐50. ">Martin‐Munoz 1989</a>) but data were reported in such a way as to be unusable for this review. <a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a> reported several carbamazepine‐associated adverse effects (allergic reactions, elevation of liver enzymes, leucopenia, EEG change). Although these tended to be more prevalent in the carbamazepine augmented group, none reached the level of statistical significance. </p> </section> </section> <section id="CD001258-sec-0151"> <h5 class="title">3.6 Physiological effects</h5> <p><a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a> and <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a> described mean plasma haloperidol to be lower in the carbamazepine‐augmented group but again these data are in the 'other data' tables. </p> </section> <section id="CD001258-sec-0152"> <h5 class="title">3.7 Missing outcomes</h5> <p>Carbamazepine is said to have an effect upon aggression. <a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a> reported that overt aggression was rated twice as severe with placebo compared to carbamazepine but no quantitative data were reported. <a href="./references#CD001258-bbs2-0004" title="EstorgesJP , LlorcaPM , LanconC , BougerolT , ScottoJC . Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale1991;17(4):307. LlorcaPM , WolfMA , LanconC , BougerolT . Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale1993;19(5):565‐71. ">Llorca 1993</a> did not find between‐group differences in SAPS or BPRS hostility and aggressiveness items but only 'P' values were presented. No data were found for 'service' outcomes such as 'duration of hospital stay'. Nor were there data on satisfaction with treatment or costs. </p> </section> <section id="CD001258-sec-0153"> <h5 class="title">3.8 Subgroup analyses</h5> <p>All subgroup analyses were only conducted on the primary outcome (less than 50% BPRS reduction). </p> <section id="CD001258-sec-0154"> <h6 class="title">3.8.1 People with treatment‐resistant schizophrenia</h6> <p><a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a> included only those with schizophrenia who had fulfilled specific criteria of neuroleptic non‐response. There was no significant difference compared to the other studies which did no have this inclusion criterion (Test for subgroup differences: Chi² = 0.28, df = 1 (P = 0.60), I² = 0%). Investigating <a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a> alone we found that significantly more patients treated with adjunctive carbamazepine improved according to the CGI and reached at least 20% BPRS reduction. However, this result was not consistent, because there were not significantly more patients treated with carbamazepine augmentation than with placebo augmentation reaching 35% and 50% BPRS reduction (primary outcome). <a href="./references#CD001258-bbs2-0004" title="EstorgesJP , LlorcaPM , LanconC , BougerolT , ScottoJC . Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale1991;17(4):307. LlorcaPM , WolfMA , LanconC , BougerolT . Clinical efficacy of bromocriptine, carbamazepine, and cyproheptadine as adjuvant to neuroleptics in 24 chronic resistant schizophrenics [Efficacite comparee de la bromocriptine, de la carbamazepine et de la cyproheptadine en association aux neuroleptiques chez 24 patients schizophrenes chroniques resistants]. Encephale1993;19(5):565‐71. ">Llorca 1993</a> examined the effectiveness of adjunctive carbamazepine in those with treatment‐resistant schizophrenia (<a href="./references#CD001258-bbs2-0131" title="KaneJM , HonigfeldG , SingerJ , MeltzerH , and the Clozaril Collaborative study group. Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45:789‐96. ">Kane 1988</a> criteria) using a cross‐over design. No mental state data were directly reported (P values only) but carbamazepine was not stated to be better than placebo in this small study (n = 12). </p> </section> <section id="CD001258-sec-0155"> <h6 class="title">3.8.2 People with EEG abnormalities</h6> <p><a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a> examined a small group of 13 relatively non‐responsive patients with EEG abnormalities, of which nine had schizophrenia. In this cross‐over trial, more patients fared somewhat better in the carbamazepine than in the placebo phase for 'leaving the study earlier', 'no global clinical improvement' and the mental state ratings (BPRS). The patient population was quite heterogeneous and diagnostic criteria were not indicated. Overall, the effects in this study did not differ significantly from the rest of the studies (Test for subgroup differences: Chi² = 0.84, df = 1 (P = 0.36), I² = 0%). </p> </section> <section id="CD001258-sec-0156"> <h6 class="title">3.8.3 People with negative symptoms</h6> <p><a href="./references#CD001258-bbs2-0007" title="NachshoniT , LevinY , LevyA , KritzA . A double‐blind trial of carbamazepine in negative symptom schizophrenia. Biological Psychiatry1994;35(1):22‐6. ">Nachshoni 1994</a> carried out a double‐blind randomised controlled trial in 28 residual patients who were suffering predominantly from negative symptoms. After five weeks no superiority of adjunctive carbamazepine compared with placebo on negative symptoms could be found. The results on the primary outcome were not different from the other studies (Test for subgroup differences: Chi² = 1.04, df = 1 (P = 0.31), I² = 3.7%). </p> </section> <section id="CD001258-sec-0157"> <h6 class="title">3.8.4 People with schizoaffective disorder</h6> <p>Only 12 people included in this review had schizoaffective disorder so analyses of this subgroup did not appear to be meaningful. </p> </section> </section> <section id="CD001258-sec-0158"> <h5 class="title">3.9 Sensitivity analyses</h5> <p>All sensitivity analyses were only applied to the primary outcome (less than 50% BPRS reduction). Therefore, only the use of a random‐effects model instead of the fixed‐effect model was relevant. There was no difference between monotherapy with antipsychotics and augmentation with carbamazepine when a random‐effects model was used (6 RCTs n = 147, RR 0.93 CI 0.60 to 1.45). </p> </section> <section id="CD001258-sec-0159"> <h5 class="title">3.10 Publication bias</h5> <p>Only six studies contributed to the primary outcome. Therefore, the funnel‐plot method was not meaningful as described in <a href="#CD001258-sec-0092">Assessment of reporting biases</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001258-sec-0160" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001258-sec-0160"></div> <section id="CD001258-sec-0161"> <h3 class="title" id="CD001258-sec-0161">Summary of main results</h3> <section id="CD001258-sec-0162"> <h4 class="title">1. General</h4> <p>Although much original data were received from trial lists, a total of 258 participants is still a small base upon which to judge the effectiveness of carbamazepine. The included studies in this review, were therefore unable to provide sufficient data to clarify the role of carbamazepine for the treatment or augmentation of antipsychotic treatment of schizophrenia and schizoaffective disorder. </p> </section> <section id="CD001258-sec-0163"> <h4 class="title">2. Comparison 1: Carbamazepine as a sole treatment versus placebo as a sole treatment</h4> <p>The little available data suggest that carbamazepine is no better than placebo for maintenance treatment. Considering that the single study contributing data (<a href="./references#CD001258-bbs2-0001" title="CarpenterWT , KurzR , KirkpatrickB , HanlonTE . Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry1991;48(1):69‐72. ">Carpenter 1991</a>) was stopped early, because the majority of those in both groups relapsed, these data are unlikely to be supplemented. </p> </section> <section id="CD001258-sec-0164"> <h4 class="title">3. Comparison 2: Carbamazepine as a sole treatment versus antipsychotics as a sole treatment </h4> <p>In the only small study available (<a href="./references#CD001258-bbs2-0010" title="SvestkaJ , CeskovaE , RysanekR , NahunekK . Controlled cross‐over comparison of carbamazepine with perphenazine in schizophrenic psychoses. Activitas Nervosa Superior1989;31(4):276‐7. ">Svestka 1989</a>), carbamazepine was not inferior when compared with perphenazine in terms of improvement of mental state and carbamazepine was associated with fewer extrapyramidal side effects than perphenazine. However, due to the small sample size of this trial (n = 38), carbamazepine can not be considered as a reasonable alternative to antipsychotics, and in the subgroup analysis in which those with schizoaffective disorder were excluded, perphenazine was superior to carbamazepine in some efficacy outcomes. </p> </section> <section id="CD001258-sec-0165"> <h4 class="title">4. Comparison 3: Adjunctive carbamazepine + antipsychotics versus placebo/no adjunctive treatment + antipsychotics </h4> <section id="CD001258-sec-0166"> <h5 class="title">4.1 Acceptability of treatment ‐ leaving the study early for any reason</h5> <p>Only 13 out of 180 people left the studies before completion with no difference between groups. This very low rate of attrition is rare within trials relevant to the care of those with schizophrenia. Adjunctive therapy of this sort seems to be very acceptable to people with schizophrenia, at least within the confines of a trial. </p> </section> <section id="CD001258-sec-0167"> <h5 class="title">4.2 General improvement</h5> <p>Two small trials (<a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a>; <a href="./references#CD001258-bbs2-0009" title="MeszarosK , SimhandlC , DenkE , LiechtensteinA , TopitzA , ThauK . A carbamazepine augmentation trial in chronic nonresponsive schizophrenia. NA1996; Vol. NA:NA. SimhandlC , MeszarosK , DenkE , ThauK , TopitzA . Adjunctive carbamazepine or lithium carbonate in therapyresistant chronic schizophrenia. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie1996;41(5):317. ">Simhandl 1996</a>) presented data on the outcome of 'no general improvement', and found a slight, but statistically significant difference between groups favouring the carbamazepine group. Little can be concluded from two small trials including 38 schizophrenia patients. It is disappointing that more trials did not report this simple outcome. </p> </section> <section id="CD001258-sec-0168"> <h5 class="title">4.3 Mental state</h5> <p>The interpretation of results on mental state has been improved by the analysis of individual patient data in a uniform way. The meta‐analysis of the data of six out of eight trials did not show a significant superiority of carbamazepine according to several levels of reduction of the Brief Psychiatric Rating Scale (BPRS) (<a href="./references#CD001258-bbs2-0142" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:790‐812. ">Overall 1962</a>). Furthermore, there was a significant heterogeneity of the study results with one study (<a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a>) showing especially bad results associated with carbamazepine augmentation. The inspection of the methods of each study did not reveal clear reasons for this heterogeneity. Therefore, current data suggest that carbamazepine augmentation of antipsychotic drugs for people with schizophrenia does not seem to have a clinically meaningful effect on mental state. However, since there was a non‐significant trend in terms of 20% BPRS reduction and since the total number of patients is still low, more trials are warranted. Specific symptoms of schizophrenia (positive symptoms, negative symptoms and depression) were only reported by one or two trials so that any meaningful statement is not possible. </p> </section> <section id="CD001258-sec-0169"> <h5 class="title">4.4 Adverse effects</h5> <p>Most data about movement disorders were too skewed to summate and individual studies reported conflicting results. As a result, no firm conclusion can be drawn. The fact that some studies found that carbamazepine augmentation leads to fewer movement disorders might be explained by a reduction in haloperidol plasma levels. This lowering of plasma levels might be the expression of an induction of liver enzymes related to carbamazepine. Two of the included studies (<a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a>; <a href="./references#CD001258-bbs2-0003" title="HesslingerB , KloseP , NormannC , LangoschJM , BergerM , WaldenJ . Carbamazepine co‐treatment in schizophrenia. Fortschritte der Neurologie Psychiatrie1998;66(4):145‐50. HesslingerB , NormannC , LangoschJM , KloseP , BergerM , WaldenJ . Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Journal of Clinical Psychopharmacology1999;19(4):310‐5. NormannC , KloseP , HesslingerB , LangoschJM , BergerM , WaldenJ . Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co‐medication: a clinical trial. Pharmacopsychiatry1997;30:204. WaldenJ , HesslingerB , NormannC , LangoschJ , BergerM . Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome. Proceedings of the 21st Congress of the Collegium Internationale Neuro‐psychopharmacologicum, Glasgow, Scotland. 1998. ">Heßlinger 1998</a>), one trial excluded because it did not provide any usable data (<a href="./references#CD001258-bbs2-0047" title="KidronR , AverbuchI , KleinE , BelmakerRH . Carbamazepine‐induced reduction of blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry1985;20(2):219‐22. ">Kidron 1985</a>), and several uncontrolled trials (<a href="./references#CD001258-bbs2-0041" title="JannMW , EreshefskyL , SakladSR , SeidelDR , DavisCM , BurchNR , et al. Effects of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology1985;5(2):106‐9. ">Jann 1985</a>; <a href="./references#CD001258-bbs2-0043" title="KahnEM , SchulzSC , PerelJM , AlexanderJE . Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology1990;10(1):54‐7. ">Kahn 1990</a>; <a href="./references#CD001258-bbs2-0082" title="OtaniK , IshidaM , YasuiN , KondoT , MiharaK , SuzukiA , et al. Interaction between carbamazepine and bromperidol. European Journal of Clinical Pharmacology1997;52(3):219. ">Otani 1997</a>) suggest that this enzyme induction occurs. This interaction must be carefully taken into account whenever carbamazepine augmentation is tried. </p> <p>Carbamazepine augmentation may well cause more allergic reactions, elevation of liver enzymes, leucopenia, and deterioration in the EEG than placebo augmentation. Adverse effects were, however, poorly reported and the only small trial (<a href="./references#CD001258-bbs2-0002" title="DoseM . Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift. Technische Universität München, 1991. DoseM , ApeltS , EmrichHM . Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research1987;22(4):303‐10. DoseM , EmrichHM . Carbamazepine as an adjunct to antipsychotic treatment. Schizophrenia Research1988;1(2,3):207‐8. DoseM , EmrichHM . Combination of neuroleptics with carbamazepine. Application in the treatment of schizophrenic psychoses [Kombination von Neuroleptika mit Carbamazepin. Einsatz in der Behandlung schizophrener Psychosen]. Münchner Medizinische Wochenschrift1990;132 (suppl 1):87‐90. DoseM , GarciaD , WeberM , YassouridisA , EmrichHM . Combined treatment of schizophrenic psychoses with neuroleptics and anticonvulsants. Pharmacopsychiatry1989;22(5):195. ">Dose 1987</a>, n = 41) that clearly reported these important events had limited power to investigate differences between groups. </p> </section> <section id="CD001258-sec-0170"> <h5 class="title">4.5 Missing outcomes</h5> <p>Currently, there are no data relating to the effect of carbamazepine augmentation on aggression, 'service' outcomes such as 'duration of hospital stay', satisfaction with treatment or costs. </p> </section> <section id="CD001258-sec-0171"> <h5 class="title">4.6 Schizophrenia sub‐types and subgroups</h5> <p>Carbamazepine augmentation was not more effective when subgroups of people with schizophrenia were the focus of the studies. People with a schizophrenic illness designated as resistant to treatment were not consistently better when they received carbamazepine augmentation. Those with negative symptoms were not different in their response to antipsychotic augmentation compared with people whose illness did not have a predominance of negative symptoms. The small <a href="./references#CD001258-bbs2-0008" title="NeppeVM . Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry1983;44(9):326‐31. NeppeVM . Carbamazepine in the psychiatric patient. Lancet1982;2(8293):334. NeppeVM . Non‐responsive psychosis ‐ a biochemical difference?. South African Medical Journal1983;63(21):797‐8. ">Neppe 1983</a> study (n = 9) suggested that a relatively non‐responsive heterogeneous group of patients with EEG abnormalities did fare somewhat better with carbamazepine augmentation than with placebo. This should be considered as hypothesis‐generating only. </p> <p>It is not clear whether it makes sense to use carbamazepine in schizophrenia(‐like) patients with 'excited states'. One randomised controlled study (<a href="./references#CD001258-bbs2-0048" title="KleinE , BentalE , LererB , BelmakerRH . Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Archives of General Psychiatry1984;41(2):165‐70. ">Klein 1984</a>) suggested that this could be useful, but data from this trial could not be used in this review as the treatment allocation of people who left the study early is unclear. In a letter the authors stated that they do not remember how to interpret the data sheets of the study. Furthermore, a large controlled study of adjunctive carbamazepine to antipsychotics in 'excited psychoses' (<a href="./references#CD001258-bbs2-0079" title="OkumaT , YamashitaI , TakahashiR , ItohH . A double‐blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatrica Scandinavica1989;80(3):250‐9. OkumaT , YamashitaI , TakahashiR , ItohH , OtsukiS , WatanabeS , et al. Comparison of the therapeutic effect of carbamazepine and placebo in schizophrenia and atypical psychosis by double blind controlled study. Rinsho Hyoka1988;16(2):327‐73. ">Okuma 1989a</a>, n = 162) had to be excluded because of the potential for inclusion of bias at the point of randomisation. Forty‐three per cent of those in the carbamazepine augmentation group showed marked and moderate improvement compared to 27% in the placebo group (not statistically significant). A post hoc analysis of individual mental state scale items suggested that this was related to an effect on disturbances of affective or emotional functions, whereas other items such as hallucinatory behaviour worsened with adjunctive carbamazepine. </p> <p>Finally, carbamazepine augmentation for those with schizoaffective disorder has been surprisingly poorly studied, although it is frequently used in the daily routine for this condition. Only 12 participants included in this review had schizoaffective disorder so any judgment on the effects of carbamazepine for this important subgroup is impossible. </p> </section> </section> </section> <section id="CD001258-sec-0172"> <h3 class="title" id="CD001258-sec-0172">Overall completeness and applicability of evidence</h3> <p>We believe that the data we gathered covered a broad spectrum of participants and problems, but the small number of included studies (due to poor quality of all available data) is too small to conclusively judge about the potential applicability of the obtained results. Trials with small sample sizes lack sufficient power to detect a small to moderate effect, and thus results from such trials are often inconclusive, even when a real effect does exist. A review has suggested that meta‐analyses based on summation of small trials should be interpreted as inconclusive, regardless of whether the combined estimate was significant (<a href="./references#CD001258-bbs2-0114" title="Davey SmithG , EggerM . Meta‐analysis: Unresolved issues and future developments. BMJ1998;16:221‐5. ">Davey Smith 1998</a>). </p> </section> <section id="CD001258-sec-0173"> <h3 class="title" id="CD001258-sec-0173">Quality of the evidence</h3> <p>The quality of all identified relevant trials has to be judged as low. As many as 64 out of 91 studies that were eventually excluded form the final analysis failed to randomise the trial sequence. Due to this low quality, only 10 studies were included in the meta‐analysis and the quality of those studies is moderate at best. Almost all studies were randomised and double‐blind but for most of them detailed descriptions were not presented. Therefore, it is unclear whether these studies were adequately randomised and whether treatment allocation was really concealed and blinding assured through the whole procedure. Reporting bias is especially prevalent in this study pool with high risk being a problem in a majority of reports. Without original study protocols and raw data sets one cannot really use those trials to the full extent. However, to the advantage of the 10 included studies is has to be noted that attrition bias was consistently judged as representing a low level of risk. The threat of other possible biases was also typically absent. Nevertheless, these limitations led to low or very low quality judgements in several important outcomes in the 'Summary of findings' table. </p> </section> <section id="CD001258-sec-0174"> <h3 class="title" id="CD001258-sec-0174">Potential biases in the review process</h3> <p>The evidence presented here is, to our best knowledge, complete. However, one can never be certain whether some additional (unpublished) material exist that was not pooled into the analysis. </p> </section> <section id="CD001258-sec-0175"> <h3 class="title" id="CD001258-sec-0175">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of only one previous unsystematic review concerning the use of carbamazepine in the treatment of schizophrenia (<a href="./references#CD001258-bbs2-0091" title="SimhandlC , MeszarosK . The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review. Journal of Psychiatry and Neuroscience1992;17(1):1‐14. ">Simhandl 1992</a>). The authors tended to a conclusion that carbamazepine could have a beneficial effect, especially when used as an adjunct treatment to other neuroleptics. We do not feel the evidence supports this stance. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001258-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Carbamazepine" data-id="CD001258-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Carbamazepine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001258-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001258-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001258-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 1 Leaving the study early." data-id="CD001258-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 1 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 2 Relapse (by 3 months)." data-id="CD001258-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 2 Relapse (by 3 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 3 Mental state: 1. Less than 20% BPRS reduction." data-id="CD001258-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 3 Mental state: 1. Less than 20% BPRS reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 4 Mental state: 2. Average endpoint score of the BPRS at 3 months." data-id="CD001258-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 4 Mental state: 2. Average endpoint score of the BPRS at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 5 Adverse effects." data-id="CD001258-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT, Outcome 5 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 1 Leaving the study early." data-id="CD001258-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 1 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 2 Mental state: 1. Categories of reduction on BPRS scores." data-id="CD001258-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 2 Mental state: 1. Categories of reduction on BPRS scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 3 Mental state: 2. Mean BPRS at endpoint." data-id="CD001258-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 3 Mental state: 2. Mean BPRS at endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 4 Adverse effects: 1. Movement disorders." data-id="CD001258-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 4 Adverse effects: 1. Movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 5 Adverse effects: 2. Others." data-id="CD001258-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 5 Adverse effects: 2. Others. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 6 Subgroup analysis ‐ schizoaffective disorder excluded ‐ Mental state: Categories of reduction on BPRS score." data-id="CD001258-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT, Outcome 6 Subgroup analysis ‐ schizoaffective disorder excluded ‐ Mental state: Categories of reduction on BPRS score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 1 Leaving the study early." data-id="CD001258-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 1 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 2 Global state: No improvement." data-id="CD001258-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 2 Global state: No improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 3 Mental state: 1a. General ‐ categories of reduction on BPRS scores." data-id="CD001258-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 3 Mental state: 1a. General ‐ categories of reduction on BPRS scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 4 Mental state: 1b. General ‐ average BPRS endpoint score (high = poor)." data-id="CD001258-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 4 Mental state: 1b. General ‐ average BPRS endpoint score (high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0020"> <p> <div class="table" id="CD001258-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Martin‐Munoz 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 8.6, SD 9.6, N = 10.<br/> 2. Placebo + antipsychotics: mean 7.4, SD 4.7, N = 10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nachshoni 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 5.0, SD 2.70, N = 15.<br/> 2. Placebo + antipsychotics: mean 5.1, SD 1.6, N = 15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neppe 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 14.7, SD 5.8, N = 3.<br/> 2. Placebo + antipsychotics: mean 22.0, SD 13.4, N = 4. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 5 Mental state: 1c. General ‐ average BPRS endpoint score (high = poor, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 6 Mental state: 1d. General ‐ average IMPS endpoint score (high = poor)." data-id="CD001258-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 6 Mental state: 1d. General ‐ average IMPS endpoint score (high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 7 Mental state: 2a. Specific ‐ positive symptoms (PANSS subscale at endpoint, high = poor)." data-id="CD001258-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 7 Mental state: 2a. Specific ‐ positive symptoms (PANSS subscale at endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0023"> <p> <div class="table" id="CD001258-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 4.9, SD 6.4, N = 16.<br/> 2. Placebo + antipsychotics: mean 7.5, SD 8.1, N = 16. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 8 Mental state: 2b. Specific ‐ positive symptoms (IMPS score at endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 9 Mental state: 2c. Specific ‐ negative symptoms (SANS at endpoint, high = poor)." data-id="CD001258-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 9 Mental state: 2c. Specific ‐ negative symptoms (SANS at endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 10 Mental state: 2d. Specific ‐ depression (Hamilton scale at endpoint, high = poor)." data-id="CD001258-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 10 Mental state: 2d. Specific ‐ depression (Hamilton scale at endpoint, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0026"> <p> <div class="table" id="CD001258-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean dose 40 mg/day, SD 36. N = 17.<br/> 2. Placebo + antipsychotics: mean dose 63 mg/day, SD 49. N = 17. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heßlinger 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + haloperidol: mean chlorprothixene dose 182 mg/day, SD 30.1. N = 9.<br/> 2. Placebo + haloperidol: mean dose 21.6 mg/day, SD 5.8. N = 9. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 11 Behaviour: Average dose of medication used for agitation (chlorprothixene, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 12 Adverse effects: 1a Movement disorders ‐ at least one movement disorder." data-id="CD001258-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 12 Adverse effects: 1a Movement disorders ‐ at least one movement disorder. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0028"> <p> <div class="table" id="CD001258-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean dose 1.3 mg/day, SD 1.6. N = 17.<br/> 2. Placebo + antipsychotics: mean dose 3.8 mg/day, SD 2.3. N = 17. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heßlinger 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + haloperidol: mean dose 3.9 mg/day, SD 0.8. N = 9.<br/> 2. Placebo + haloperidol: mean dose 2.9 mg/day, SD 1.0 N = 9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simhandl 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean dose 2.67 mg/day, SD 2.89. N = 15.<br/> 2. Placebo + antipsychotics: mean dose 2.67 mg/day, SD 4.62. N = 12. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 13 Adverse effects: 1b. Movement disorders ‐ average dose of antiparkinsonism drugs (biperiden, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0029"> <p> <div class="table" id="CD001258-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 1.03, SD 0.86. N = 17.<br/> 2. Placebo + antipsychotics: mean 2.84, SD 2.18. N = 17. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nachshoni 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 0.9, SD 0.9. N = 13.<br/> 2. Placebo + antipsychotics: mean 0.4, SD 0.5. N = 13. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simhandl 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 0.27, SD 0.19. N = 15.<br/> 2. Placebo + antipsychotics: mean 0.31, SD 0.35. N = 12. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 14 Adverse effects: 1c. Movement disorders ‐ average endpoint score (SAS, high = poor, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0029">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0030"> <p> <div class="table" id="CD001258-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Simhandl 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean 7.1, SD 0.2. N = 15.<br/> 2. Placebo + antipsychotics: mean 13.1, SD 14.2. N = 12. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 15 Adverse effects: 1d. Movement disorders ‐ average endpoint TD rating (high = poor, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0030">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 16 Adverse effects: 2. Others." data-id="CD001258-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 16 Adverse effects: 2. Others. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0032"> <p> <div class="table" id="CD001258-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + antipsychotics: mean level 5.8 (mg haloperidol/d)/(microgms/L haloperidol), SEM 3.3. N = 17.<br/> 2. Placebo + antipsychotics: mean level 3.1 (mg haloperidol/d)/(microgms/L haloperidol), SEM 1.65. N = 17. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heßlinger 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine + haloperidol: mean haloperidol level change ‐3.8 ng/mL, SD 3.0. N = 9 (˜45% decrease).<br/> 2. Placebo + haloperidol: mean haloperidol level change 1.9 ng/mL, SD 2.3. N = 9 (˜51% increase). </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 17 Physiological effect: Haloperidol plasma levels. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0032">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001258-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 18 Subgroup analysis ‐ treatment‐resistant participants." data-id="CD001258-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 18 Subgroup analysis ‐ treatment‐resistant participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 19 Subgroup analysis ‐ EEG abnormalities." data-id="CD001258-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 19 Subgroup analysis ‐ EEG abnormalities. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 20 Subgroup analysis ‐ negative symptoms." data-id="CD001258-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 20 Subgroup analysis ‐ negative symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001258-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/urn:x-wiley:14651858:media:CD001258:CD001258-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_t/tCD001258-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 21 Sensitivity analysis: random effects model ‐ less than 50% BPRS reduction." data-id="CD001258-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 21 Sensitivity analysis: random effects model ‐ less than 50% BPRS reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/media/CDSR/CD001258/image_n/nCD001258-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD001258-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reviews or additional comparisons</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Category</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>Additional comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine (+/‐ antipsychotics) versus lithium (+/‐ antipsychotics)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0015" title="BellaireW , DemischK , StollK‐D . Carbamazepine vs. lithium. Application in the prophylaxis of recidivating affective and schizoaffective psychoses [Carbamazepin vs. Lithium. Einsatz in der Prophylaxe rezidivierender affektiver und schizoaffektiver Psychosen]. Münchner Medizinische Wochenschrift1990;132:82‐6. ">Bellaire 1990</a>, <a href="./references#CD001258-bbs2-0034" title="GreilW , Ludwig‐MayerhoferW , ErazoN , EngelRR . Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. European Archives of Psychiatry and Clinical Neuroscience1997;247(1):42‐50. ">Greil 1997</a>, <a href="./references#CD001258-bbs2-0043" title="KahnEM , SchulzSC , PerelJM , AlexanderJE . Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology1990;10(1):54‐7. ">Kahn 1990</a>, <a href="./references#CD001258-bbs2-0052" title="LenziA , LazzeriniF , GrossiE , MassimettiG , PlacidiGF . Use of carbamazepine in acute psychosis: A controlled study. Journal of International Medical Research1986;14(2):78‐84. ">Lenzi 1986</a>, <a href="./references#CD001258-bbs2-0085" title="PlacidiGF , LenziA , LazzeriniF , CassanoGB . The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double‐blind 3‐year trial in 83 patients. Journal of Clinical Psychiatry1986;47(10):490‐4. PlacidiGF , LenziA , RampelloE , AndreaniMF , CassanoGB , GrossiE . Long term‐double blind prospective study on carbamazepine versus lithium in bipolar and schizoaffective disorders. Preliminary results. In: EmrichHM , OkumaT editor(s). Anticonvulsants in Affective Disorders. Amsterdam: Elsevier, 1984:188‐97. ">Placidi 1986</a>, <a href="./references#CD001258-bbs2-0090" title="SchulzSC , ConleyRR , KahnEM , et al. Nonresponders to neuroleptics: a distinct subtype. Schizophrenia: scientific progress. New York: Oxford University Press, Date of publication and page numbers not indicated. SchulzSC , KahnEM , BakerRW , et al. Lithium and carbamazepine augmentation in treatment‐refractory schizophrenia. The Neuroleptic‐Nonresponsive Patient: Characterization and Treatment. Washington DC: American Psychiatric Press, 1990:111‐36. ">Schulz 1990</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine plus one antipsychotic versus another antipsychotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0078" title="OhlmeierMD , JahnK , Wilhelm‐GosslingC , Godecke‐KochT , HoffmannJ , SeifertJ , et al. Perazine and carbamazepine in comparison to olanzapine in schizophrenia. Neuropsychobiology2007;55(2):81‐8. [MEDLINE: 17570951] ">Ohlmeier 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine versus valproate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0069" title="Mosca LD//Licciardo JP//CoppolaJL . A double‐blind carbamazepine‐controlled efficacy and safety study of valproate in impulsivity and violence. 11th Congress of The European College of Neuropsychopharmacology; Oct 31 ‐ Nov 4, Paris, France. 1998. [MEDLINE: CONFERENCE ABSTRACT] ">Mosca 1998</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Different formulations of carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0077" title="NijdamJR , DoorschotCH , vanBavelLP , LoonenAJ . A comparison of carbamazepine Divitabs and a normal carbamazepine preparation in psychiatric and oligophrenic patients. Pharmacopsychiatry1992;25(3):145‐9. [MEDLINE: 92342659] ">Nijdam 1992</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxcarbazepine versus lithium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0019" title="CabreraJ , AlbrechtJ , Muller‐OerlinghausenB . Combined preventive treatment of recurrent manic‐depressive disease with lithium and carbamazepine or oxcarbazepine. Nervenarzt1987;58(4):245‐9. ">Cabrera 1987</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Existing review*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine versus typical antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0023" title="CovellNH , WeissmanEM , EssockSM . Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia Bulletin2004;30(2):229‐40. [MEDLINE: 15279042; EMBASE 2004274059] ">Covell 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><b>New review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adrenochrome semicarbazone for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0094" title="SugermanAA , HyamsL . Electroencephalographic effects of adrenochrome semicarbazone in schizophrenia: quantitative amplitude analysis. Research Communications in Chemical Pathology and Pharmacology1970;1(1):86‐98. [MEDLINE: 72091267; PMID 4944698] ">Sugerman 1970</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydroxyphenamate for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0063" title="MillerMJ , ShettelR , FiedlerHT . Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines. Psychosomatics1965;6(5):340‐2. [MEDLINE: 66013834; PMID 5319246] ">Miller 1965</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rimcazole for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0017" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27(2):103‐6. [MEDLINE: 92021349; PMID 1681560] ">Borison 1991</a>, <a href="./references#CD001258-bbs2-0070" title="MunetzMR , SchulzSC , BellinM , HartyI . Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Development Research1989;16(1):79‐83. [MEDLINE: 83197879; PMID 6342171] ">Munetz 1989</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tybamate for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0060" title="MeshelE , DenberHC . Double‐blind study of tybamate in psychotic patients. Diseases of the Nervous System1967;28(5):311‐3. [MEDLINE: 67165839; PMID 5338174] ">Meshel 1967</a>, <a href="./references#CD001258-bbs2-0061" title="MeshelE , DenberHC . The use of tybamate in psychotic patients. (A further double blind study). Diseases of the Nervous System1968;29(4):243‐5. [MEDLINE: 68271597; PMID 4870945] ">Meshel 1968</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin B6 for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001258-bbs2-0064" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 add‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. [MEDLINE: 14518160; EMBASE 2003374828; CN‐00440574.] ">Miodownik 2003</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>* <a href="./references#CD001258-bbs2-0121" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174] ">Essali 2009</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reviews or additional comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001258-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: random.<br/> Blinding: blind or independent raters.<br/> Duration: minimum one year follow‐up. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: people with schizophrenia whose illness is resistant to treatment; people with psychoses and EEG abnormalities; people with psychoses and aggressive behaviour; and people with schizoaffective disorders.<br/> Age: Sex: male and female.<br/> N = 750. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Carbamazepine/oxcarbazepine alone: any dose.<br/> 2. Placebo (or no intervention).<br/> 3. Carbamazepine/oxcarbazepine in combination with any antipsychotic treatment: any dose.<br/> 4. Placebo (or no intervention) in combination with any antipsychotic treatment.<br/> 5. Antipsychotics alone: any dose. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving the study early.</p> <p>Service utilisation.</p> <p>Global state ‐ no clinically important change.*</p> <p>Relapse.</p> <p>Mental state ‐ no clinically important change.</p> <p>Behaviour ‐ no clinically important change.</p> <p>Social functioning ‐ no clinically important change.<br/> Adverse effects ‐ clinically important general adverse effects*; sudden and unexpected death. </p> <p>Economic outcomes.</p> <p>Satisfaction with treatment.</p> <p>Quality of life.</p> <p>Pharmacokinetic interactions.<br/> <br/> All outcomes by time ‐ short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Primary outcomes of interest.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design for future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001258-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Adjunctive carbamazepine + antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>adjunctive Carbamazepine + antipsychotics compared to placebo/no adjunctive treatment + antipsychotics for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with schizophrenia<br/> <b>Settings:</b> Outpatients/ inpatients<br/> <b>Intervention:</b> Adjunctive Carbamazepine + antipsychotics<br/> <b>Comparison:</b> Placebo/no adjunctive treatment + antipsychotics </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo/no adjunctive treatment + antipsychotics</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Adjunctive Carbamazepine + antipsychotics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> <br/> Leaving the study early due to any reason<br/> Follow‐up: mean 7.7 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>51 per 1000</b> <br/> (17 to 145) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> <br/> (0.16 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No clinically important change in general mental state</b> <br/> Scale used: less than 50% BPRS reduction<br/> Follow‐up: mean 6.1 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b> <br/> (418 to 698) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.67 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average endpoint general mental state score</b> <br/> Scale used: Average BPRS endpoint score. Scale from: 0 to 108.<br/> Follow‐up: mean 5.7 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global mental state in the control groups was<br/> <b>BPRS total score points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global mental state in the intervention groups was<br/> <b>0.3 higher</b> <br/> (12.49 lower to 13.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average endpoint positive symptom score</b> </p> <p>Scale used: Mean PANSS positive subscore at endpoint. Scale from: 7 to 49.<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean positive symptoms in the control groups was<br/> <b>PANSS positive subscore</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean positive symptoms in the intervention groups was<br/> <b>4.22 higher</b> <br/> (0.75 to 7.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average endpoint depressive symptom score</b> <br/> Scale used: Hamilton scale at endpoint. Scale from: 0 to 54.<br/> Follow‐up: mean 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression in the control groups was<br/> <b>Hamilton scale at endpoint</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression in the intervention groups was<br/> <b>0.35 lower</b> <br/> (2.2 lower to 1.5 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aggression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: reporting bias is especially prevalent in this study pool with high risk being a problem in a majority of reports.<br/> <sup>2</sup> Inconsistency: differences between studies (number of events, effects size sometimes in favour of carbamazepine sometimes in favour of no treatment).<br/> <sup>3</sup> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.<br/> <sup>4</sup> Imprecision: 95% confidence interval includes both benefit and harm. Moreover, the number of events was small.<br/> <sup>5</sup> Inconsistency: high heterogeneity of trial results<br/> <sup>6</sup> Imprecision: very small population size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Adjunctive carbamazepine + antipsychotics compared with placebo/no adjunctive treatment + antipsychotics for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/full#CD001258-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001258-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.17, 6.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse (by 3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.78, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. Less than 20% BPRS reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.75, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 2. Average endpoint score of the BPRS at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.46, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 allergic reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.44 [0.42, 132.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 blood dyscrasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [0.14, 72.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001258-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.52 [0.23, 88.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. Categories of reduction on BPRS scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 less than 20% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.62, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 less than 35% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.86, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 less than 50% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.78, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 2. Mean BPRS at endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐3.84, 8.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 1. Movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 6.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 use of anticholinergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.09, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 2. Others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.04, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 collapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.3 [0.03, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.04, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.52 [0.23, 88.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.04, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.4 [0.72, 40.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 nausia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.12, 62.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.12, 62.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.28, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Subgroup analysis ‐ schizoaffective disorder excluded ‐ Mental state: Categories of reduction on BPRS score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 less than 20% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [1.22, 7.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 less than 35% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.15, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 less than 50% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.94, 2.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001258-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.16, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: No improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.37, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1a. General ‐ categories of reduction on BPRS scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 less than 20% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.44, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 less than 35% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.57, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 less than 50% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1b. General ‐ average BPRS endpoint score (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.21 [‐7.82, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1c. General ‐ average BPRS endpoint score (high = poor, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 1d. General ‐ average IMPS endpoint score (high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.61 [1.30, 7.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2a. Specific ‐ positive symptoms (PANSS subscale at endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [0.75, 7.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2b. Specific ‐ positive symptoms (IMPS score at endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2c. Specific ‐ negative symptoms (SANS at endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.75 [‐6.71, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2d. Specific ‐ depression (Hamilton scale at endpoint, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐2.20, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Behaviour: Average dose of medication used for agitation (chlorprothixene, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 1a Movement disorders ‐ at least one movement disorder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 1b. Movement disorders ‐ average dose of antiparkinsonism drugs (biperiden, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 1c. Movement disorders ‐ average endpoint score (SAS, high = poor, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 1d. Movement disorders ‐ average endpoint TD rating (high = poor, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 2. Others <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 allergic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [0.16, 87.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 EEG deterioration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.59, 7.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 liver enzyme elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [0.53, 12.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 white blood cell decline (substantial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.09, 19.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Physiological effect: Haloperidol plasma levels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Subgroup analysis ‐ treatment‐resistant participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 treatment‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.51, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 not treatment‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.65, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Subgroup analysis ‐ EEG abnormalities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 with EEG abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.65, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 without EEG abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Subgroup analysis ‐ negative symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 predominant negative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.83, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 no predominant negative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.55, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Sensitivity analysis: random effects model ‐ less than 50% BPRS reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.60, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001258.pub3/references#CD001258-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001258.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001258-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001258-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001258-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001258-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001258-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001258-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD001258-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001258\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001258\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001258\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001258\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001258\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001258.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001258.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001258.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001258.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001258.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717648564"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001258.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717648568"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001258.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbd0f1a9f9371',t:'MTc0MDcxNzY1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 